West China Hospital
四川大学华西医院
Listed for 46 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at West China Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌44 papers led2 open trials led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌71 papers led6 open trials led
- Hepatocellular carcinoma肝细胞癌392 papers led16 open trials led
- Stomach cancer胃癌168 papers led4 open trials led
- Hepatoblastoma肝母细胞瘤4 papers led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Chordoma脊索瘤3 papers led
- Osteosarcoma骨肉瘤36 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤33 papers led
- Neuroblastoma神经母细胞瘤5 papers led2 open trials led
- Ewing sarcoma尤文肉瘤9 papers led
- Multiple myeloma多发性骨髓瘤59 papers led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
- Aplastic anaemia再生障碍性贫血4 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症12 papers led
- Beta thalassaemiaβ 地中海贫血2 papers led
- Haemophilia A血友病 A4 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜2 papers led
- Fanconi anaemia范可尼贫血1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病36 papers led
- IgG4-related diseaseIgG4相关性疾病11 papers led
- Myasthenia gravis重症肌无力16 papers led
- Moyamoya disease烟雾病11 papers led
- Biliary atresia胆道闭锁7 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎22 papers led
- Takayasu arteritis大动脉炎3 papers led
- Hepatic echinococcosis肝包虫病14 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化31 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症60 papers led
- Spinal muscular atrophy脊髓性肌萎缩症1 paper led
- Fabry disease法布雷病5 papers led
- Pompe disease庞贝病2 papers led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Behçet disease白塞病6 papers led
- Alport syndromeAlport 综合征2 papers led
- IgA nephropathyIgA 肾病34 papers led
- Gaucher disease戈谢病0 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎11 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎3 papers led
- Congenital diaphragmatic hernia先天性膈疝5 papers led
- Hirschsprung disease先天性巨结肠1 paper led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症4 papers led
- Hereditary angioedema遗传性血管性水肿2 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
Not listed for: Atypical haemolytic uraemic syndrome, Wilson disease, Niemann–Pick disease type C, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 44 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.8%.
5 hospitals in Chengdu for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 7
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIntratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07625423
Age 18 years to 65 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07035626
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT06839066
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan
- RecruitingPrevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07311772
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai
- Recruiting40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07328854
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai
- RecruitingReduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Phase
- Phase 3
- Started
- 2024-03
- Registry
- NCT06239727
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang
- RecruitingAdebrelimab and Chemoradiotherapy in High-risk LANPC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06349889
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led44
- Tumor Treatment Response-Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma.
- Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.
- Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.
- Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
- Head-to-Head Comparison of 68 Ga-DOTATATE and 18 F-FDG PET in EBV-Positive Nonkeratinizing Nasopharyngeal Carcinoma.
- Neutrophil-to-Lymphocyte Ratio as a Predictor for PD-L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma.
- Recurrent Patterns in Patients With Nasopharyngeal Caricinoma and Risks Leading to Inaccurate Delineation in Marginal Failure in the Era of Intensity-Modulated Radiotherapy.
- Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis.
- Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
- Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
- Unveiling the complex double-edged sword role of exosomes in nasopharyngeal carcinoma.
- Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.
- Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression.
- Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma.
- Association between time from diagnosis to treatment and survival of patients with nasopharyngeal carcinoma: A population-based cohort study.
- Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
- Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
- Incidence and Risk Factors for Radiotherapy-Induced Oral Mucositis Among Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.
- Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
- Primary Hepatocellular Carcinoma Revealed on 68 Ga-DOTATATE in a Patient With Nasopharyngeal Carcinoma.
- A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.
- First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
- LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion.
- Screening of core genes and prediction of ceRNA regulation mechanism of circRNAs in nasopharyngeal carcinoma by bioinformatics analysis.
- Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
- Acquired unilateral alopecia after arterial infusion chemotherapy in a recurrent nasopharyngeal carcinoma.
- Quantitative Comparisons of Deep-learning-based and Atlas-based Auto- segmentation of the Intermediate Risk Clinical Target Volume for Nasopharyngeal Carcinoma.
- Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma.
- Local radiotherapy versus nonradiotherapy to distant lesions for metastatic nasopharyngeal carcinoma: Retrospective cohort study.
- The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis.
- Automatic Delineation of Gross Tumor Volume Based on Magnetic Resonance Imaging by Performing a Novel Semisupervised Learning Framework in Nasopharyngeal Carcinoma.
- Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
- Computed tomography-based deep-learning prediction of induction chemotherapy treatment response in locally advanced nasopharyngeal carcinoma.
- A nomogram for predicting late radiation-induced xerostomia among locoregionally advanced nasopharyngeal carcinoma in intensity modulated radiation therapy era.
- Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era.
- IncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2.
- Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
- m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma.
- Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma.
- Assessment of different induction chemotherapy regimens in locally advanced nasopharyngeal carcinoma: Meta-analysis.
- Nomograms for predicting survival outcomes in intensity-modulated radiotherapy era of nasopharyngeal carcinoma: A study based on Epstein-Barr virus DNA biological responses.
- Clinical and survival analysis of nasopharyngeal carcinoma with consistently negative Epstein-Barr virus DNA.
- Weight Change Trajectory in Patients With Locally Advanced Nasopharyngeal Carcinoma During the Peri-Radiation Therapy Period.
- A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status17
- Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
- A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
- A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
- Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy
- Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
- Adebrelimab and Chemoradiotherapy in High-risk LANPC
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
- The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer
- Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
More papers found outside PubMed (not counted)52
- 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma
- 728eP Real-world outcomes of a contrast-enhanced ultrasound–integrated follow-up strategy in the management of N3 nasopharyngeal carcinoma after radiotherapy
- A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.
- Spontaneous resolution of laryngeal contact granuloma following radiotherapy for nasopharyngeal carcinoma: A case report
- Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
- The value of imaging techniques based on enhanced magnetic resonance imaging in the diagnosis and prediction response of radiotherapy for nasopharyngeal carcinoma
- Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car
- VER-155008-functionalized Au-polydopamine blackspheres for heat shock proteins 70-targeted near-infrared II region photothermal therapy
- Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.
- Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
- Characterizing the impact of sarcopenia on treatment response and survival in previously treated recurrent or metastatic nasopharyngeal carcinoma: Insights from a secondary analysis of the KL-A167 randomized trial.
- Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
- Efficacy of nimotuzumab added to concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma.
- Elucidating the Immune Microenvironment and Therapeutic Targets in Nasopharyngeal Carcinoma through Bioinformatics
- Evaluation of Adjuvant Chemotherapy after Induction Chemotherapy and Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Propensity Score-Matched Analysis
- Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).
- Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial.
- 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma
- A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
- Advancing Delineation of Gross Tumor Volume Based on Magnetic Resonance Imaging by Performing Source-Free Domain Adaptation in Nasopharyngeal Carcinoma
- Automatic Head-and-Neck Tumor Segmentation in MRI via an End-to-End Adversarial Network
- Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Long-Term Outcomes of Stereotactic Body Radiation Therapy with or without PD-1 Inhibitors in Metastatic Nasopharyngeal Carcinoma
- Medicine in Nasopharyngeal Carcinoma
- PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)
- Radiation-induced MDM4 contributes to radioresistant nasopharyngeal carcinoma (NPC) via impaired TP53 transcriptional activity and activated BNIP3-mediated mitophagy
- Research on Longitudinal change trends and influencing factors of eating behaviour in patients with nasopharyngeal carcinoma undergoing radiotherapy
- A phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2).
- Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Mitoxantrone hydrochloride liposome injection in the treatment of recurrent/metastatic head and neck cancers: A multicenter, open-label, single-arm, phase Ⅰb study.
- Multi-transSP: Multimodal Transformer for Survival Prediction of Nasopharyngeal Carcinoma Patients
- The changes of xerostomia and caries risk induced by radiotherapy under the protection of the personalized PMMA oral stents in nasopharyngeal carcinoma patients: a preliminary prospective study
- The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–2019
- 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
- A Novel Dosimetric Metrics-Based Risk Model to Predict Local Recurrence in Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiation Therapy
- DA-DSUnet: Dual Attention-based Dense SU-net for automatic head-and-neck tumor segmentation in MRI images
- Efficient Semi-supervised Gross Target Volume of Nasopharyngeal Carcinoma Segmentation via Uncertainty Rectified Pyramid Consistency
- JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- Malposition of a Nasogastric Feeding Tube Into the Right Pleural Cavity of a Nasopharyngeal Carcinoma Patient After Radiotherapy and Chemotherapy: A Case Report
- Semi-supervised NPC segmentation with uncertainty and attention guided consistency
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 71 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 2.4%.
3 hospitals in Chengdu for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 9
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIntensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07519486
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Registry
- NCT06753747
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingOncolytic Virus in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07061704
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingLow-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06446726
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingNeoantigen Vaccines in Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06675201
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingEndostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07154108
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07700667
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- Not yet recruitingStandardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07769658
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou University; 5 listed hospitals as study sitesChengdu, Guangzhou, Kunming, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led71
- Preoperative Physiological Reserve and Pathological Response as Independent Predictors of Survival in Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy.
- Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.
- 68Ga-FAPI and 18F-FDG PET/CT for predicting pathologic response and progression-free survival in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
- Efficacy of adjuvant immunotherapy and immunochemotherapy in esophageal squamous cell carcinoma: A retrospective cohort study.
- Does Pseudo-Lymph Node Skip Metastasis After Neoadjuvant Therapy Affect Esophageal Squamous Cell Carcinoma Outcomes? A Multicenter Study.
- Artificial intelligence in endoscopic diagnosis of esophageal squamous cell carcinoma and precancerous lesions.
- The Efficacy of Time Interval Between Neoadjuvant Chemoimmunotherapy and Surgery on Outcomes in Oesophageal Squamous Cell Carcinoma.
- Expression and prognostic value of estrogen-related receptor β alternative splicing isoforms in esophageal squamous cell carcinoma.
- Real-world survival benefit of adding immunotherapy to chemotherapy in esophageal cancer: A large SEER-based analysis.
- Personalized neoantigen DC vaccine combined with camrelizumab following definitive therapy in locally advanced unresectable esophageal squamous cell carcinoma (CHANT-241): protocol for a randomized controlled trial.
- A circRNA promotes esophageal squamous cell carcinoma progression by inhibiting TRIM25-mediated degradation of IGF2BP family members.
- Spatial transcriptomic analysis of tumor microenvironment in esophageal squamous cell carcinoma with HIV infection.
- Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.
- Esophageal squamous cell carcinoma with EP300 mutations displays distinct genetic characteristics relevant to neoadjuvant chemoradiotherapy.
- Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma.
- Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
- Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma.
- Nomogram for predicting pathologic complete response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
- A platform of functional studies of ESCC-associated gene mutations identifies the roles of TGFBR2 in ESCC progression and metastasis.
- Mapping of lymph node metastasis from esophageal squamous cell carcinoma after neoadjuvant treatment: a prospective analysis from a high-volume institution in China.
- A novel tumor staging system incorporating cN status for stratifying early stage esophageal squamous cell carcinoma patients after trimodal therapy.
- Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.
- A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma.
- Does increasing the number of resected lymph nodes really improve the prognosis of patients with esophageal squamous cell carcinoma?
- Impact of deep muscle invasion on nodal status and survival in patients with pT2 esophageal squamous cancer.
- Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.
- Prognostic factors for patients with pathologic T1-T2N+ esophageal squamous cell carcinoma: A retrospective study with external validation.
- Correlation between tumor budding and the long-term follow-up outcomes after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma.
- Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions - Authors' reply.
- Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial.
- Identifying TOPK and Hypoxia Hallmarks in Esophageal Tumors for Photodynamic/Chemo/Immunotherapy and Liver Metastasis Inhibition with Nanocarriers.
- Longer Time Interval from Neoadjuvant Chemoradiation to Surgery is Associated with Poor Survival for Patients Without Clinical Complete Response in Oesophageal Cancer.
- ASO Author Reflections: Timing of Oesophagectomy After Neoadjuvant Chemoradiotherapy for Locally Advanced Oesophageal Cancer.
- Esophageal squamous cell carcinoma presenting as a submucosal tumor.
- Pararespiratory and paradigestive lymph node metastases in esophageal squamous cell carcinoma: predicting survival and refining the N staging system.
- ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma.
- Identification and Validation of Co-Expressed Immune-Related Gene Signature Affecting the Pattern of Immune Infiltrating in Esophageal Cancer.
- Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma.
- Artificial intelligence for detecting and delineating a small flat-type early esophageal squamous cell carcinoma under multimodal imaging.
- MTHFD1L confers a poor prognosis and malignant phenotype in esophageal squamous cell carcinoma by activating the ERK5 signaling pathway.
- Artificial intelligence for detecting and delineating the extent of superficial esophageal squamous cell carcinoma and precancerous lesions under narrow-band imaging (with video).
- The investigation of volatile organic compounds in diagnosing (early) esophageal squamous cell carcinoma and gastric adenocarcinoma.
- Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics.
- Development and validation of a model to determine the risk of esophageal strictures after endoscopic submucosal dissection for esophageal neoplasms.
- Lymphovascular and Perineural Invasion After Neoadjuvant Therapy in Esophageal Squamous Carcinoma.
- Risk factors and a predictive nomogram for lymph node metastasis in superficial esophageal squamous cell carcinoma.
- Association of the Modified Albumin-Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma.
- Overexpressed COL3A1 has prognostic value in human esophageal squamous cell carcinoma and promotes the aggressiveness of esophageal squamous cell carcinoma by activating the NF-κB pathway.
- Artificial Intelligence for Detecting and Delineating Margins of Early ESCC Under WLI Endoscopy.
- The comparisons of neoadjuvant chemoimmunotherapy versus chemoradiotherapy for oesophageal squamous cancer.
- Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.
- Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma.
- Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
- Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.
- A Commentary on "The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation" [Int. J. Surg. (
- The minimum number of examined lymph nodes for accurate nodal staging and optimal survival of stage T1-2 esophageal squamous cell carcinoma: A retrospective multicenter cohort with SEER database validation.
- Artificial intelligence for detecting superficial esophageal squamous cell carcinoma under multiple endoscopic imaging modalities: A multicenter study.
- Characterization of distinct circular RNA signatures in solid tumors.
- Identifying a confused cell identity for esophageal squamous cell carcinoma.
- Raman spectroscopy and machine learning for the classification of esophageal squamous carcinoma.
- Artificial intelligence for diagnosing microvessels of precancerous lesions and superficial esophageal squamous cell carcinomas: a multicenter study.
- Prognostic Role of Nodal Skip Metastasis in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Study.
- ASO Author Reflections: Nodal Skip Metastasis Is Associated with Survival Benefit in Thoracic Esophageal Squamous Cell Carcinoma.
- The interaction of TEA domain transcription factor 4 (TEAD4) and Yes-associated protein 1 (YAP1) promoted the malignant process mediated by serum/glucocorticoid regulated kinase 1 (SGK1).
- PIWIL2 interacting with IKK to regulate autophagy and apoptosis in esophageal squamous cell carcinoma.
- Fc fragment of immunoglobulin G receptor IIa (FCGR2A) as a new potential prognostic biomarker of esophageal squamous cell carcinoma.
- Identification of Epithelial-Mesenchymal Transition- (EMT-) Related LncRNA for Prognostic Prediction and Risk Stratification in Esophageal Squamous Cell Carcinoma.
- Combination of Modified Free Anterolateral Thigh Skin-Fascia Flap and Pedicled Thoracoacromial Artery Perforator Flap for Entire Circumferential Pharyngoesophageal Defect and External Neck Skin Defect Reconstructions.
- Role of nodal skip metastasis in patients with mid-thoracic oesophageal squamous cell carcinoma: a propensity score matching study.
- Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
- Surgical Treatment for an Esophageal Carcinoma With a Pancreatic Pseudocyst.
All its trials on ClinicalTrials.gov, any status27
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
- Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
- Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC
- Oncolytic Virus in Esophageal Squamous Cell Carcinoma
- Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
- Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
- Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma
- Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
- Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
- Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
- Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC
- A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
- A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)62
- 013. VALUE OF COMBINING THE NUMBER OF LYMPH NODE STATIONS AND TUMOR REGRESSION GRADE IN THE NEOADJUVANT TREATMENT OF ESOPHAGEAL CANCER
- 035. THE EFFECT OF SURGICAL INTERVAL POST-NEOADJUVANT CHEMOIMMUNOTHERAPY ON LONG-TERM OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 089. SPECTRAL CT-BASED NON-INVASIVE PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE AND POSTOPERATIVE LYMPH NODE METASTASIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 097. TARGETING FUSOBACTERIUM NUCLEATUM WITH MRNA-LNP VACCINES RESTORES PD-1 SENSITIVITY AND REPROGRAMS THE TUMOR MICROENVIRONMENT IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 121. EFFICIENCY INDEX OF LYMPH NODE DISSECTION FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER NEOADJUVANT THERAPY
- 138. MULTI-CENTER CLINICAL ANALYSIS AND SINGLE-CELL SEQUENCING INSIGHTS INTO THE DEVELOPMENTAL MECHANISMS OF SYNCHRONOUS MULTIPLE PRIMARY ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 142. PREDICTIVE ROLE OF CTDNA IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA RECEIVING NEOADJUVANT IMMUNOTHERAPY AND CHEMOTHERAPY: A PROSPECTIVE COHORT STUDY
- 143. LONG-TERM DYSPHAGIA AND REGURGITATION IN 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS: PREVALENCE, CORRELATES, AND PREDICTIVE MODELS IN A MULTI-CENTER COHORT
- 149. DOES PSEUDO-LYMPH NODE SKIP METASTASIS AFTER NEOADJUVANT THERAPY AFFECT ESOPHAGEAL SQUAMOUS CELL CARCINOMA OUTCOMES?—A MULTICENTER STUDY
- 206. ENO1 LACTYLATION AS A PROMISING PREDICTIVE BIOMARKER AND THERAPEUTIC TARGET FOR ESCC METASTASIS
- 207. LOW-DOSE INVOLVED-FIELD RT, PLUS IMMUNOCHEMOTHERAPY SHOWED EXCELLENT EFFICACY AND LOW TOXICITIES IN UNRESECTABLE LA-ESCC: A PROSPECTIVE PHASE II STUDY
- 279. GENOMIC COPY NUMBER IDENTIFIES DRIVER MUTATIONS OF METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 321. CTHRC1-MEDIATED MEGAKARYOCYTE/PLATELET INFILTRATION IN THE TUMOR MICROENVIRONMENT PROMOTES IMMUNOTHERAPY RESISTANCE IN ESCC
- 329. COMPARISON OF TWO DIFFERENT END-TO-END HAND-SEWN ANASTOMOSES IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE STUDY
- 387. RNA M6A METHYLATION PROMOTES TUMOR DEVELOPMENT AND WASF3 TRANSLATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC).
- Conversion Surgery for cT4b Esophageal Squamous Cell Carcinoma
- Predictive factors for treatment response to neoadjuvant PD-1 inhibitor and chemotherapy in locally advanced esophageal squamous cell carcinoma
- Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis
- Uniportal versus multiportal video-assisted thoracic surgery for esophageal cancer: a randomized clinical trial
- 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- 235. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY
- 236. THE ROLE OF ADJUVANT THERAPY FOLLOWING NEOADJUVANT CHEMORADIOTHERAPY AND ESOPHAGECTOMY IN ESOPHAGEAL CANCER
- 240. CACHEXIA INDEX AS A POTENTIAL BIOMARKER FOR SENSITIVITY OF NEOADJUVANT THERAPY AND PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 384. NEOADJUVANT ANLOTINIB COMBINED WITH PENPULIMAB FOR RESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC): A PROSPECTIVE, SINGLE-ARM, PHASE II TRIAL
- 398. DYSPHAGIA OR REGURGITATION AND ITS CORRELATES AMONG UP TO 10-YEAR ESOPHAGEAL SQUAMOUS CELL CARCINOMA SURVIVORS
- 424. EFFECT OF GUT MICROBIOTA ON THE RESPONSE TO NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 436. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD
- 439. INTEGRATION OF SCRNA-SEQ AND BULK RNA-SEQ TO VALIDATE A PROGNOSTIC ASSOCIATED SIGNATURE IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 626. DO CALCIUM CHANNEL BLOCKERS AFFECT CLINICAL OUTCOMES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH HYPERTENSION? A MULTICENTER RETROSPECTIVE STUDY
- 798. FEASIBILITY AND EFFICACY OF CISPLATIN, PACLITAXEL AND IMMUNE CHECKPOINT INHIBITORS AS CONVERSION THERAPY FOR LOCOREGIONALLY UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- A Phase II Clinical Trial of Sintilimab Combined with Lower Dose Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
- Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
- Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial.
- 14. IMPACTS OF ADDITIONAL CYCLES OF NEOADJUVANT IMMUNOCHEMOTHERAPY ON ESOPHAGECTOMY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
- 186. PROGNOSTIC ROLE OF NODAL SKIP METASTASIS IN THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A LARGE-SCALE MULTICENTER STUDY
- 187. PROGNOSTIC IMPACT OF LYMPH NODE HARVEST FOR PATIENTS WITH NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A LARGE-SCALE MULTICENTER STUDY
- 188. VITAMIN D RECEPTOR INDUCES OXIDATIVE STRESS TO PROMOTE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PROLIFERATION VIA THE P53 SIGNALING PATHWAY
- 189. IDENTIFICATION OF M6A-RELATED SIGNATURE GENES IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA BY MACHINE LEARNING METHOD
- 24. A NOVEL TUMOR STAGING SYSTEM INCORPORATING CN STATUS FOR STRATIFYING EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS AFTER TRIMODAL THERAPY
- 401. THE ADJUVANT IMMUNOTHERAPY COMBINATIONS FOLLOWING ESOPHAGECTOMY FOR RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WITH NEOADJUVANT THERAPY
- 402. LYMPH NODE METASTASIS MAPPING IN T1–2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 430. MAPPING OF LYMPH NODE METASTASIS FROM ESCC AFTER NEOADJUVANT TREATMENT: A PROSPECTIVE ANALYSIS FROM A HIGH-VOLUME INSTITUTION IN CHINA
- 444. SHOULD T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA BE SUBCLASSIFIED WITH RESPECT TO LYMPH NODE INVOLVEMENT AND SURVIVAL?
- 485. MATTHEW EFFECT OF NEOADJUVANT THERAPY IN ESOPHAGEAL CANCER
- Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway
- P-60 Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: A single-arm phase II clinical trial
- 137. THE COMPARISON OF SHORT-TERM OUTCOMES BETWEEN NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY AND NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS CANCER
- 153. APPLICATION OF RAMAN SPECTROSCOPY AND MACHINE LEARNING IN THE CLASSIFICATION OF ESOPHAGEAL SQUAMOUS CARCINOMA
- 231. A NOMOGRAM BASED ON BODY MASS INDEX CHANGES TO PREDICT PROGNOSIS AFTER CURATIVE RESECTION OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
- 241. A VALIDATED NOMOGRAM PREDICTING LYMPH NODE METASTASIS OF T2N0 ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOR CLINICAL DECISION-MAKING
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p
- Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- MiR-4739 inhibits the malignant behavior of esophageal squamous cell carcinoma cells via the homeobox C10/vascular endothelial growth factor A/phosphatidylinositol 3-kinase/AKT pathway
- 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha
- 820 EFFICACY AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR SUPERFICIAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA AND PRECANCEROUS LESIONS
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
- Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 392 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 2.6%.
5 hospitals in Chengdu for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 23
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
- Phase
- Early phase 1
- Started
- 2026-01
- Registry
- NCT07295262
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSafety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07295275
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 2 listed hospitals as study sitesBeijing, Chengdu, Xuzhou
- RecruitingDiagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
- Phase
- Not given
- Started
- 2026-01
- Registry
- NCT07295340
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSurgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2026-03
- Registry
- NCT07410715
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingPULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- Phase
- Phase 2
- Started
- 2026-04
- Registry
- NCT07463248
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-02
- Registry
- NCT07482059
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingTextbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06950827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingPD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-10
- Registry
- NCT07053072
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingApplication of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07077356
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07106827
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingPD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06742424
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingApplication of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
- Phase
- N/A
- Started
- 2023-12
- Registry
- NCT06219096
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingIntegration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- Phase
- Not given
- Started
- 2027-01
- Registry
- NCT07912853
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingSafety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- Phase
- N/A
- Started
- 2026-04
- Registry
- NCT07480382
Age 18 years to 80 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingYMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07580261
Age 18 years to 70 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingSurgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2026-12
- Registry
- NCT07866612
Age 18 years to 80 years (registered criteria)
Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingPhase 2 Study of WGI-0301 for Advanced HCC
- Phase
- Phase 2
- Started
- 2024-07
- Registry
- NCT06309485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Registry
- NCT05652920
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai
- Not yet recruitingNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07356037
Age 18 years to 85 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led392
- Radiofrequency ablation is safe in patients with hepatocellular carcinoma and thrombocytopenia.
- Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.
- 3D fractal dimension analysis of CT imaging for microvascular invasion prediction in hepatocellular carcinoma.
- Laparoscopic liver resection is superior to open liver resection for hepatocellular carcinoma patients with BCLC stage 0-A hepatocellular carcinoma and portal hypertension.
- Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.
- Ultrasound shear wave viscoelastic imaging combined with shear wave elastography for characterization of focal liver lesions.
- Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review.
- Multicenter study on right Glissonean pedicle management in laparoscopic right hepatectomy: main trunk vs. sectoral pedicle transection approaches.
- Laparoscopic versus open hepatectomy in hepatocellular carcinoma patients with high-risk pathological features: a multicenter propensity score-matched study.
- Impact of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease on Hepatocellular Carcinoma Incidence and Long-Term Prognosis Post-Liver Resection: A Systematic Review and Meta-Analysis.
- Perfluorohexane nanodroplet-assisted mechanical high intensity focused ultrasound cavitation: A strategy for hepatocellular carcinoma treatment.
- Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study.
- Prognostic Impact of the Pathologic Response of Patients with Hepatocellular Carcinoma After Preoperative Treatments.
- Development and validation of a small-sample machine learning model to predict 5-year overall survival in patients with hepatocellular carcinoma.
- Low preoperative serum creatinine levels are associated with poor prognosis in patients with hepatocellular carcinoma after liver resection: a multicenter study.
- Nomogram for predicting early cancer-related death due to recurrence after liver resection in hepatocellular carcinoma patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C: a multicenter study.
- Discovery of targeting USP10-mediated proline metabolism arrangement to inhibit hepatocellular carcinoma progression.
- Histone lactylation facilitates MCM7 expression to maintain stemness and radio-resistance in hepatocellular carcinoma.
- Utilizing liquid-liquid biopolymer regulators to predict the prognosis and drug sensitivity of hepatocellular carcinoma.
- Radiotherapy enhances triple therapy for conversion and survival in patients with unresectable hepatocellular carcinoma with portal vein tumor thrombus.
- Textbook outcome and survival following laparoscopic versus open right hemihepatectomy for hepatocellular carcinoma: A propensity score-matched study.
- Performance of simultaneous multislice diffusion-weighted imaging using monoexponential, intravoxel incoherent motion, and diffusion kurtosis models: assessment of microvascular invasion and histologic grade in hepatocellular carcinoma.
- Recent Advancements in Known and Emerging Risk Factors of Hepatocellular Carcinoma.
- Preoperative Hepatic Augmentation Versus Transarterial Chemoembolization for Hepatocellular Carcinoma With Insufficient Remnant Liver Volume: A Systematic Review and Meta-Analysis.
- Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma.
- Halting hepatocellular carcinoma: Identifying intercellular crosstalk in HBV-driven disease.
- circCEP70 encoded protein inhibits the progression of hepatocellular carcinoma.
- EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism.
- Tenofovir vs Entecavir on the Prognosis of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Resection: The Role of HBsAg Levels.
- Acute cutaneous adverse drug reactions in hepatocellular carcinoma patients undergoing combined targeted and immunotherapy: unraveling the impact of dosage and interval.
- Long-Term Outcome of Repeat Resection versus Radiofrequency Ablation for Intrahepatic Recurrence after Curative Resection of Hepatocellular Carcinoma Initially within Barcelona Clinic Liver Cancer Staging System 0-A Stages: A Multicenter St
- Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.
- Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.
- Validation of the Iwate scoring system for the stratification of laparoscopic liver resections: An international multicenter study.
- MRI-based prediction of microvascular invasion/high tumor grade and adjuvant therapy benefit for solitary HCC ≤ 5 cm: a multicenter cohort study.
- MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma.
- Deep learning-based 3D quantitative total tumor burden predicts early recurrence of BCLC A and B HCC after resection.
- Temporal evolution of the LI-RADS radiation treatment response assessment on multiphase CT/MRI in patients undergoing selective internal radiation therapy for hepatocellular carcinoma.
- Preoperative prediction of early recurrence in hepatocellular carcinoma using simultaneous multislice diffusion kurtosis imaging.
- ANK3 Is Regulated by Recursive Splicing and Inhibits Hepatocellular Carcinoma Metastasis by Inhibiting E-Cadherin Protein Degradation.
- The role of bile acid metabolism-related genes in prognosis assessment of hepatocellular carcinoma and identification of NPC1 as a biomarker.
- Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy.
- Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor.
- Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy.
- Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC.
- The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma.
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
- PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma.
- Multisite long-read sequencing reveals the early contributions of somatic structural variations to HBV-related hepatocellular carcinoma tumorigenesis.
- Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth by inhibiting Hippo signaling in HCC.
- Identification of Core gene expression alterations regulated by gut microbiota in tumor progression and immunotherapy resistance through integrative pan-cancer analysis.
- The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma.
- Fractal analysis based on Gd-EOB-DTPA-enhanced MRI for prediction of vessels that encapsulate tumor clusters in patients with hepatocellular carcinoma.
- Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis.
- Advancements in elucidating the mechanisms of Sorafenib resistance in hepatocellular carcinoma.
- Integrative analysis of senescence-related genes identifies robust prognostic clusters with distinct features in hepatocellular carcinoma.
- DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K/AKT Pathway.
- Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
- CD44 and mitochondria dual-targeted polydopamine nanoplatform for combined chemotherapy, photothermal ablation, and immunogenic cell death induction in liver cancer.
- Wild-Type and rtA181T/sW172* Mutant Strains of Hepatitis B Virus Drive Hepatocarcinogenesis via Distinct GRP78-Mediated ER Stress Pathways.
- A Soluble Triantennary N-Acetylgalactosamine Camptothecin Prodrug for Hepatocellular Carcinoma-Targeted Therapy.
- MMAE-Based Peptide-Drug Conjugates Targeting GPC3 for Precision Chemoradiotherapy in Hepatocellular Carcinoma.
- Structure-Guided Optimization and Preclinical Evaluation of 6-O-Benzylguanine-Based Pin1 Inhibitor for Hepatocellular Carcinoma Treatment.
- Synergistic Ultrasound-Activable Artificial Enzyme and Precision Gene Therapy to Suppress Redox Homeostasis and Malignant Phenotypes for Controllably Combating Hepatocellular Carcinoma.
- A prognostic score based on early recurrence-related factors for hepatocellular carcinoma patients with microvascular invasion after hepatectomy.
- Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.
- MRI-Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in HCC.
- Unveiling causal links between serum amino acid levels and risk of hepatobiliary neoplasms by Mendelian randomization study.
- Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects.
- FBP1 controls liver cancer evolution from senescent MASH hepatocytes.
- The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment.
- Loss of NUMB promotes hepatomegaly and hepatocellular carcinoma through the AKT/glycogen/hippo signaling.
- RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.
- CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91/HLA-A *0201 exhibit potent activity against HBV-HCC.
- Immunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.
- Hypoxia-induced exosomal lncRNA-PVT1 as a biomarker and mediator of EMT in hepatocellular carcinoma.
- EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy.
- Progressed Atrioventricular Block in Immune Checkpoint Inhibitor Induced Myocarditis: A Case Report.
- Identification and functional analysis of five hub lncRNAs associated with oncogenesis of Hepatocellular Carcinoma.
- Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis.
- Histone lactylation drives liver cancer metastasis by facilitating NSF1-mediated ferroptosis resistance after microwave ablation.
- Comprehensive multi-phase 3D contrast-enhanced CT imaging for primary liver cancer.
- Integrating bulk and single cell sequencing data to identify prognostic biomarkers and drug candidates in HBV associated hepatocellular carcinoma.
- Preparation of iodine-131 labeled Polyvinyl alcohol-collagen microspheres for radioembolization therapy of liver tumors.
- TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis.
- KAT2A-driven succinylation of SRSF11 enforces spliceosome-mediated RAD52 splicing to promote homologous recombination and radioresistance in hepatocellular carcinoma.
- Ultrasensitive Electrochemical Screening of Circulating Tumor Cells Over Single-Atom Nanozyme Integrated 3D Nanoarray.
- Indocyanine green fluorescence staining-guided laparoscopic posterosuperior segmentectomy: A multicenter retrospective cohort study.
- Indocyanine green fluorescence imaging (ICG-FI) in difficult laparoscopic hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matched analysis.
- Comparison of textbook outcomes between laparoscopic and open liver resection for patients with hepatocellular carcinoma: a multicenter study.
- Effect of 15- or 25-min intermittent Pringle maneuver on early recurrence of hepatocellular carcinoma after hepatectomy: a protocol for a randomized controlled trial.
- Short- and long-term outcomes following laparoscopic liver resection for hepatocellular carcinoma combined with type I/II portal vein tumor thrombus.
- Three-dimensional location approach with silk thread guided hepatectomy for liver tumor.
- Current status of drug therapy for chronic hepatitis B.
- Intraoperative Blood Transfusion has a Distinct Impact on the Long-Term Prognosis of Hepatocellular Carcinoma Patients With Different Alpha-Fetoprotein-Tumor Burden Scores After Liver Resection: A Large-Scale Multicenter Study.
- Therapeutic efficacy of hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a propensity score matching study.
- Predictive value of combined Albumin-Globulin score and psoas muscle index for postoperative prognosis in combined hepatocellular carcinoma and cholangiocarcinoma.
- Short- and medium-term impacts of unplanned intraoperative conversion during laparoscopic liver resection for hepatocellular carcinoma patients: a propensity score-matched study.
- Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade.
- Quantitative diffusion weighted imaging in patients with hepatocellular carcinoma: effects of simultaneous multi-slice acceleration and gadoxetic acid administration.
- Diagnostic performance of magnetic resonance imaging and contrast-enhanced ultrasound in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma: a meta-analysis.
- Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma.
- The Impact of Imaging-Diagnosed Sarcopenia on Long-term Prognosis After Curative Resection for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- Oxidative Stress Promotes Liver Cancer Metastasis via RNF25-Mediated E-Cadherin Protein Degradation.
- Dual Enzyme-Locked Activation Reporter for Accurate Liver Cancer Surveillance.
- Steric Hindrance-Mediated Enzymatic Reaction Enable Homogeneous Dual Fluorescence Indicators Aptasensing of Hepatocellular Carcinoma CTCs.
- Pure Laparoscopic Anatomic Resection of Liver Segment 4 with Middle Hepatic Vein Involvement Using Indocyanine Green Fluorescence Staining.
- Laparoscopic Anatomical Cranial Sub-segmentectomy of Segment VII (S7) with Super-Selective Intra-arterial Nano-ICG Positive Staining-Guided Trans-Parenchymal Approach.
- Laparoscopic Anatomic Bi-segmentectomy (S5 and S6) Using Takasaki's Approach and Indocyanine Green Fluorescence Navigation.
- Novel CAR-T cells targeting TRKB for the treatment of solid cancer.
- Transhepatic arterial approaches for ICG injection to guide laparoscopic anatomical hepatectomy: A case series study.
- Enhanced prognosis of HCC patients undergoing radical treatments with tenofovir versus entecavir: A meta-analysis based on propensity score matching studies.
- Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B.
- Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: A literature review.
- Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma.
- Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
- Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.
- Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
- Identification of CD8+ T-cell exhaustion signatures for prognosis in HBV-related hepatocellular carcinoma patients by integrated analysis of single-cell and bulk RNA-sequencing.
- Evaluating the diagnostic accuracy of heat shock proteins and their combination with Alpha-Fetoprotein in the detection of hepatocellular carcinoma: a meta-analysis.
- The effectiveness of problem-based learning and case-based learning teaching methods in clinical practical teaching in TACE treatment for hepatocellular carcinoma in China: a bayesian network meta-analysis.
- Prognostic significance of cyclin-dependent kinase subunit 2 (CKS2) in malignant tumours: a meta-analysis and bioinformatic analysis.
- Inhibiting Pink1/Parkin-mediated mitophagy enhances the anticancer effects of quercetin in hepatocellular carcinomaf.
- DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma.
- UBAP2 contributes to radioresistance by enhancing homologous recombination through SLC27A5 ubiquitination in hepatocellular carcinoma.
- A facile boronophenylalanine modified polydopamine dual drug-loaded nanoparticles for enhanced anti-tumor immune response in hepatocellular carcinoma comprehensive treatment.
- The role of cholesterol-modified prognostic nutritional index in nutritional status assessment and predicting survival after liver resection for hepatocellular carcinoma.
- PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.
- Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.
- Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
- NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
- SUMOylation of annexin A6 retards cell migration and tumor growth by suppressing RHOU/AKT1-involved EMT in hepatocellular carcinoma.
- Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis.
- Hyperpolarized 13 C MRI in hepatocellular carcinoma: Unmet questions during clinical translation.
- Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
- A refined therapeutic plan based on the machine-learning prognostic model of liver hepatocellular carcinoma.
- Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma.
- Extracellular contrast agent-enhanced MRI is as effective as gadoxetate disodium-enhanced MRI for predicting microvascular invasion in HCC.
- Meta-analysis of prognostic factors for overall survival and disease-free survival among resected patients with combined hepatocellular carcinoma and cholangiocarcinoma.
- Tumor burden score is superior to primary liver cancer stages in predicting prognosis for patients with combined hepatocellular-cholangiocarcinoma after surgery: A multi-center study.
- Prognostic MRI features to predict postresection survivals for very early to intermediate stage hepatocellular carcinoma.
- Apparent diffusion coefficient and tissue stiffness are associated with different tumor microenvironment features of hepatocellular carcinoma.
- miRNAs in patients with alcoholic liver disease: a systematic review and meta-analysis.
- Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma.
- Targeting cell death mechanisms: the potential of autophagy and ferroptosis in hepatocellular carcinoma therapy.
- Extrachromosomal circular MiR-17-92 amplicon promotes HCC.
- Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC.
- Letter to the Editor: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
- BMP9-ID1 Pathway Attenuates N6-Methyladenosine Levels of CyclinD1 to Promote Cell Proliferation in Hepatocellular Carcinoma.
- NIR-II-Absorbing NDI Polymer with Superior Penetration Depth for Enhanced Photothermal Therapy Efficiency of Hepatocellular Carcinoma.
- Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study.
- A commentary on 'Global research status and frontiers on autophagy in hepatocellular carcinoma: a comprehensive bibliometric and visualized analysis'.
- A commentary on 'Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study'.
- A commentary on 'Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study'.
- Inhibition of NPC1 suppresses cell proliferation and β-catenin signaling activation of liver cancer.
- A flexible deep learning framework for liver tumor diagnosis using variable multi-phase contrast-enhanced CT scans.
- Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma.
- Integrated Single-Cell and Spatial Transcriptome Reveal Metabolic Gene SLC16A3 as a Key Regulator of Immune Suppression in Hepatocellular Carcinoma.
- Oxidative stress induces extracellular vesicle release by upregulation of HEXB to facilitate tumour growth in experimental hepatocellular carcinoma.
- RNA-binding protein Trx regulates alternative splicing and promotes metastasis of HCC via interacting with LINC00152.
- Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma.
- Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
- Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.
- Treatments for Early Hepatocellular Carcinoma: Resection or Ablation-How to Make a Decision.
- Deep learning-based compressed SENSE improved diffusion-weighted image quality and liver cancer detection: A prospective study.
- Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies.
- Combining a glycolysis‑related prognostic model based on scRNA‑Seq with experimental verification identifies ZFP41 as a potential prognostic biomarker for HCC.
- Focal liver lesion diagnosis with deep learning and multistage CT imaging.
- FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma.
- METTL3-mediated m6A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.
- Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis.
- Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
- Comprehensive analysis of bioinformatics and system biology reveals the association between Girdin and hepatocellular carcinoma.
- Prognostic Implications of MRI-assessed Intratumoral Fat in Hepatocellular Carcinoma: An Asian and European Cohort Study.
- LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.
- Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
- Hypoxia-induced nuclear localization of ubiquinol-cytochrome-c reductase complex assembly factor 3 (UQCC3) in hepatocellular carcinoma.
- Use of indocyanine green-human serum albumin complexes in fluorescence image-guided laparoscopic anatomical liver resection: a case series study (with video).
- Impact of metabolic dysfunction-associated fatty liver disease on the outcomes following laparoscopic hepatectomy for hepatocellular carcinoma.
- Caudo-dorsal approach combined with the occlusion of right hepatic vein and Pringle maneuver in laparoscopic anatomical resection of segment 7.
- Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
- Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial.
- Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection.
- Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.
- Laparoscopic Anatomical Resection of Paracaval Portion of Caudate Lobe and Segment 8 for HCC in an HCV-Related Cirrhotic Patient.
- Remarkable response of PD-1 antibody plus lenvatinib as the second-line treatment for combined hepatocellular-cholangiocarcinoma: Report of two cases.
- Gamma-glutamyl transpeptidase to albumin ratio holds a prognostic significance after hepatectomy in patients with hepatocellular carcinoma and liver cirrhosis.
- Efficacy of LR-5 and LR-4/5 by Liver Imaging Reporting and Data System (MRI) for hepatocellular carcinoma: A meta-analysis.
- Rupture and hemorrhage of a large primary liver tumor in caudate lobe.
- Hepatocyte-specific HDAC3 ablation promotes hepatocellular carcinoma in females by suppressing Foxa1/2.
- Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis.
- A new method for predicting the microvascular invasion status of hepatocellular carcinoma through neural network analysis.
- The prognostic nutritional index and tumor pathological characteristics predict the prognosis of elderly patients with early-stage hepatocellular carcinoma after surgery.
- FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
- Incidence and trends of hepatic cancer among children and adolescents in the United States from 2000 to 2017: Evidence from the Surveillance, Epidemiology, and End Results registry data.
- Effect of PIVKA-II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery.
- Insurance status impacts survival of hepatocellular carcinoma patients after liver resection.
- Risk factors of postoperative bile leakage after liver resection: A systematic review and meta-analysis.
- Repeat hepatic resection combined with intraoperative radiofrequency ablation versus repeat hepatic resection alone for recurrent and multiple hepatocellular carcinoma patients meeting the Barcelona Clinic Liver Cancer stage A: A propensity
- Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.
- HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.
- DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis.
- Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
- Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma.
- Primary Hepatocellular Carcinoma Revealed on 68 Ga-DOTATATE in a Patient With Nasopharyngeal Carcinoma.
- The value of MRI in predicting hepatocellular carcinoma with cytokeratin 19 expression: a systematic review and meta-analysis.
- Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma.
- EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
- TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
- Dysregulated cholesterol regulatory genes in hepatocellular carcinoma.
- Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.
- Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.
- Preoperative MRI-based multiparametric model for survival prediction in hepatocellular carcinoma patients with portal vein tumor thrombus following hepatectomy.
- Nomogram to predict liver surgery-specific complications for hepatocellular carcinoma: A multicenter study.
- Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study.
- Intravoxel incoherent motion diffusion weighted imaging for preoperative evaluation of liver regeneration after hepatectomy in hepatocellular carcinoma.
- Quality of radiomics for predicting microvascular invasion in hepatocellular carcinoma: a systematic review.
- Ferroptosis signaling promotes the release of misfolded proteins via exosomes to rescue ER stress in hepatocellular carcinoma.
- HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma.
- Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk.
- Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression.
- The appropriate method of hepatectomy for hepatocellular carcinoma within University of California San Francisco (UCSF) criteria through neural network analysis.
- Clinical prognosis and related molecular features of hepatitis B-associated adolescent and young adult hepatocellular carcinoma.
- HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
- Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
- Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.
- USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination‑mediated degradation.
- Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: a randomized controlled trial.
- Liver cancer stem cell dissemination and metastasis: uncovering the role of NRCAM in hepatocellular carcinoma.
- Parenchymal Sparing Laparoscopic Segmentectomy III and IV with Indocyanine Green Fluorescence Negative Stain Method Using Glisson Pedicle Approach.
- Meta-analysis of Prognostic Factors for Overall Survival Among Resected Patients with Spontaneous Ruptured Hepatocellular Carcinoma.
- The current role of radiofrequency ablation in the treatment of intrahepatic recurrent hepatocellular carcinoma.
- Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
- Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection.
- Discovery of canine drug toceranib phosphate as a repurposed agent against human hepatocellular carcinoma.
- circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
- PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma.
- Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
- Hollow MnO2-Based Nanoprobes for Enhanced Photothermal/Photodynamic /Chemodynamic Co-Therapy of Hepatocellular Carcinoma.
- Upper-critical solution temperature (UCST) polymer functionalized nanomedicine for controlled drug release and hypoxia alleviation in hepatocellular carcinoma therapy.
- Universal Liver Imaging Lexicon: Imaging Atlas for Research and Clinical Practice.
- Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
- Development of a Model including MRI Features for Predicting Advanced-stage Recurrence of Hepatocellular Carcinoma after Liver Resection.
- Hepatocellular Carcinoma: It Is Time to Focus on Prognosis.
- Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives.
- VICT2 Trait: Prognostic Alternative to Peritumoral Hepatobiliary Phase Hypointensity in HCC.
- Prognostic nomograms for HBV-related BCLC 0-a stage hepatocellular carcinoma incorporating aspartate aminotransferase to albumin ratio.
- Targeting PSAT1 to mitigate metastasis in tumors with p53-72Pro variant.
- Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma.
- Hierarchically tumor-activated nanoCRISPR-Cas13a facilitates efficient microRNA disruption for multi-pathway-mediated tumor suppression.
- The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
- Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial.
- Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: a systematic review of propensity score-matched studies.
- Treatments for recurrent hepatocellular carcinoma: laparoscopic or open repeat liver resection, how to make a decision?
- Hepatitis B Virus X Protein Modulates p90 Ribosomal S6 Kinase 2 by ERK to Promote Growth of Hepatoma Cells.
- Simultaneous Homogeneous Fluorescence Detection of AFP and GPC3 in Hepatocellular Carcinoma Clinical Samples Assisted by Enzyme-Free Catalytic Hairpin Assembly.
- 131I-Labeled Silk Fibroin Microspheres for Radioembolic Therapy of Rat Hepatocellular Carcinoma.
- Association of the Modified Albumin-Bilirubin Grade with Survival Outcomes in Esophageal Squamous Cell Carcinoma.
- Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas.
- ASO Author Reflections: How to Choose the Optimal Strategy to Treat Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas?
- ASO Author Reflections: Pure Laparoscopic Right Upper Transversal Hepatectomy.
- Pure Laparoscopic Right Upper Transversal Hepatectomy.
- ASO Author Reflections: How to Choose the Optimal Surgical Strategy to Finish Laparoscopic Anatomical Hepatectomy for a Solitary HCC in the Left Lobe?
- Laparoscopic Segmentectomy IV Using Hepatic Round Ligament Approach Combined with Fluorescent Negative Staining Method.
- Primary hepatic gastrointestinal stromal tumor: A case series.
- Effects of preoperative oral carbohydrate administration combined with postoperative early oral intake in elderly patients undergoing hepatectomy with acute-phase inflammation and subjective symptom burden: A prospective randomized controll
- Novel postoperative nomograms for predicting individual prognoses of hepatitis B-related hepatocellular carcinoma with cirrhosis.
- Preoperative aspartate aminotransferase to albumin ratio correlates with tumor characteristics and predicts outcome of hepatocellular carcinoma patients after curative hepatectomy: a multicenter study.
- Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.
- The impact of tumor burden at the initial hepatectomy on the recurrence-to-death survival after repeat surgical resection/radiofrequency ablation: a retrospective study.
- Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis.
- Liver transplantation in China: Achievements over the past 30 years and prospects for the future.
- The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.
- Use of chemotherapy to treat hepatocellular carcinoma.
- A detailed multi-omics analysis of GNB2 gene in human cancers.
- The lipid transporter HDLBP promotes hepatocellular carcinoma metastasis through BRAF-dependent epithelial-mesenchymal transition.
- Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
- Prognostic value of exosomal noncoding RNA in hepatocellular carcinoma: a meta-analysis.
- New classification-oriented laparoscopic anatomical hepatectomy strategy for hepatocellular carcinoma invading two or more (sub)segments in the left lobe.
- Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
- Conversion resection for patients with hepatocellular carcinoma and inferior vena cava tumor thrombus: a consecutive case series.
- Safety of elective hepatectomy performed on weekend for patients with hepatocellular carcinoma.
- Upregulation of SERPINE2 Results in Poor Prognosis of Hepatoblastoma via Promoting Invasion Abilities.
- Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis.
- Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease.
- Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System.
- Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma.
- Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.
- The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis.
- Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study.
- A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients.
- Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging.
- Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
- A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma.
- Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
- Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population.
- Overexpression of transcription factor 3 drives hepatocarcinoma development by enhancing cell proliferation via activating Wnt signaling pathway.
- Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
- Association of the MARCO polymorphism rs6761637 with hepatocellular carcinoma susceptibility and clinical characteristics.
- Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
- The role and mechanism of noncoding RNAs in regulation of metabolic reprogramming in hepatocellular carcinoma.
- BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
- Hemihepatic versus total hepatic inflow occlusion for laparoscopic hepatectomy: A randomized controlled trial.
- Benefit of a Live Donor for Patients With Hepatocellular Carcinoma on the Waiting List.
- Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.
- OGG1 contributes to hepatocellular carcinoma by promoting cell cycle-related protein expression and enhancing DNA oxidative damage repair in tumor cells.
- A cascaded copper-based nanocatalyst by modulating glutathione and cyclooxygenase-2 for hepatocellular carcinoma therapy.
- LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC.
- TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
- A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.
- Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma.
- Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
- Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
- The Value of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis.
- Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions.
- Predicting microvascular invasion in hepatocellular carcinoma: A dual-institution study on gadoxetate disodium-enhanced MRI.
- Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling.
- UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination.
- Transarterial chemoembolization vs. liver resection as initial treatment for hepatocellular carcinoma occurring exclusively in caudate lobe: A retrospective propensity matching analysis.
- A Macrophage Differentiation-Mediated Gene: DDX20 as a Molecular Biomarker Encompassing the Tumor Microenvironment, Disease Staging, and Prognoses in Hepatocellular Carcinoma.
- Uvangoletin, extracted from Sarcandra glabra, exerts anticancer activity by inducing autophagy and apoptosis and inhibiting invasion and migration on hepatocellular carcinoma cells.
- HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma.
- A randomized controlled trial of effect of 15- or 25-minute intermittent Pringle maneuver on hepatectomy for hepatocellular carcinoma.
- Patterns, timing, and predictors of recurrence after laparoscopic liver resection for hepatocellular carcinoma: results from a high-volume HPB center.
- Laparoscopic anatomic bi-segmentectomy (S3 and S4b) using the Glisson's pedicle-first and intrahepatic anatomic markers approach.
- Trocar layouts in laparoscopic liver surgery.
- Is the anterior approach suitable for laparoscopic right hemihepatectomy in patients with large HCC (5-10 cm)? A propensity score analysis.
- Radioactive Iodine Therapy Does not Improve Cancer-specific Survival in Hürthle Cell Carcinoma of the Thyroid.
- Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis.
- Four-year experience with more than 1000 cases of total laparoscopic liver resection in a single center.
- Differentiating malignant and benign focal liver lesions in children using CEUS LI-RADS combined with serum alpha-fetoprotein.
- Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma.
- Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma.
- Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
- The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study.
- Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
- Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages.
- The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells.
- The prognostic value of aspartate aminotransferase-to-lymphocyte ratio index in early-stage hepatocellular carcinoma after hepatectomy: A propensity-score matched analysis.
- 18-FDG PET/CT provides solid evidence of microvascular invasion and is correlated with prognosis in patients with hepatocellular carcinoma.
- Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis.
- Comparison of preoperative two-dimensional shear wave elastography, indocyanine green clearance test and biomarkers for post hepatectomy liver failure prediction in patients with hepatocellular carcinoma.
- Postoperative controlling nutritional status score is an independent risk factor of survival for patients with small hepatocellular carcinoma: a retrospective study.
- Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.
- The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus.
- Combination of albumin-bilirubin grade and clinically significant portal hypertension predicts the prognosis of patients with hepatocellular carcinoma after liver resection.
- Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma.
- Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
- Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy.
- Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
- Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
- Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
- YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
- Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
- MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.
- The importance of a nonsmooth tumor margin and incomplete tumor capsule in predicting HCC microvascular invasion on preoperative imaging examination: a systematic review and meta-analysis.
- HBV upregulated triggering receptor expressed on myeloid cells-1 (TREM-1) expression on monocytes participated in disease progression through NF-Kb pathway.
- Prediction of Remnant Liver Regeneration after Right Hepatectomy in Patients with Hepatocellular Carcinoma Using Preoperative CT Texture Analysis and Clinical Features.
- Laparoscopic liver resection for hepatocellular carcinoma presents less respiratory complications compared with open procedure: A propensity score analysis in the elderly.
- Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging.
- Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
- Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
- LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.
- Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.
- Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma.
- Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin.
- Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
- Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in Patients With CHB.
- Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.
- The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
- Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF)
- Prognostic evaluation and immune infiltration analysis of five bioinformatic selected genes in hepatocellular carcinoma.
- The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection.
- Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma.
- Baseline HBV-DNA load plus AST/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: A multicentre study.
- Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
- Donafenib treatment for hepatocellular carcinoma: A case report.
- Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report.
- Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis.
- Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy.
- Diabetes mellitus affects long-term survival in hepatitis B virus-related hepatocellular carcinoma patients: A propensity score-matched analysis.
- Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients.
- Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma.
- Intermedin facilitates hepatocellular carcinoma cell survival and invasion via ERK1/2-EGR1/DDIT3 signaling cascade.
- Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
- Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial.
- Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR.
- Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases.
- Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis.
- Comprehensive radiomics nomogram for predicting survival of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
- Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.
- The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis.
Chinese-language papers (not in the count)8
- [Surgical management of multinodular hepatocellular carcinoma: controversies,opportunities,and challenges].
- Expression of signal recognition particle 14 in hepatocellular carcinoma and its relationship with disease progression and patient survival.
- [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
- [Evaluation of clinical safety and diagnostic efficacy of domestic liver-specific magnetic resonance contrast agent (gadoxetate disodium)].
- [Prognosis prediction model for hepatocellular carcinoma based on autophagy related genes].
- [Fucoidan-Modified Phase-Transitional Contrast Agent for Ultrasound Imaging and Targeting of Hepatoma Cells].
- [Mechanism of miRNA-3679 Inhibiting Downstream ZADH2-Target Genes to Promote Hepatocellular Carcinoma Cell Proliferation].
- [Impact of treatment compliance in chronic hepatitis B].
All its trials on ClinicalTrials.gov, any status65
- Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
- YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
- Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
- A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
- NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
- Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
- Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
- Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
- PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
- A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
- Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
- Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
- Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
- Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
- Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
- Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
- Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy
- RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
- Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase 2 Study of WGI-0301 for Advanced HCC
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
- Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
- The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
- Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
- A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
Cancer
Stomach cancer
胃癌Led 168 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.7%.
5 hospitals in Chengdu for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 15
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingXELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Registry
- NCT06742411
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingPerioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
- Phase
- Phase 2
- Started
- 2026-02
- Registry
- NCT07374250
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Not yet recruitingMannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07655661
Age 18 years to 75 years (registered criteria)
Led by West China HospitalChengdu
- Enrolling by invitationNon-surgical Management After NIT for dMMR/MSI-H GC
- Phase
- Not given
- Started
- 2026-07
- Registry
- NCT07646574
Age 18 years to Not stated (registered criteria)
Led by West China HospitalChengdu
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingOral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2026-06
- Registry
- NCT07552402
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan
- RecruitingAssessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07127822
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06221748
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingA Phase 2 Clinical Study of ABSK061 and ABSK043
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06632262
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingA Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT07923214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai
- RecruitingComparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2023-04
- Registry
- NCT05918094
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChengdu, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05262491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin
- Not yet recruitingComparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
- Phase
- Not given
- Started
- 2025-07
- Registry
- NCT07088744
Age 18 years to 80 years (registered criteria)
Led by Changhai Hospital; 1 listed hospital as study siteChengdu, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led168
- The trajectories and predictors of cancer-related fatigue in gastric cancer patients during chemotherapy: A longitudinal study using growth mixture modeling.
- The association between pathological complete response and prognosis of gastric or adenocarcinoma of esophagogastric junction cancer following neoadjuvant chemotherapy: A meta-analysis.
- Intraperitoneal metastasis of gastric cancer: new insights on resident macrophages.
- HER2 regulates autophagy and promotes migration in gastric cancer cells through the cGAS-STING pathway.
- Prognostic value of nutritional risk assessment indices in patients with digestive system tumors.
- Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis.
- Trends in incidence and mortality of early-onset gastrointestinal cancers: a comprehensive study.
- Burden of gastrointestinal cancers in Asia, 1990-2019.
- Laparoscopic versus open distal gastrectomy with D2 lymphadenectomy following neoadjuvant chemotherapy for locally advanced gastric cancer (CLASS-03b): protocol for a multicentre, randomised, controlled, non-inferiority trial.
- Dihydroartemisinin suppresses metastatic potential and induces apoptosis in gastric adenocarcinoma: An integrative experimental and computational analysis revealing inhibition of MMP14 and promotion of oxidative stress.
- Perioperative chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: A systematic review and meta-analysis.
- Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.
- METTL3-driven m⁶A epigenetics in gastric cancer: unveiling oncogenic networks and clinical translation from tumorigenesis to therapy resistance.
- Proportion and Characteristics of Helicobacter Pylori -Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Systematic Review and Meta-Analysis.
- 18 F-FDG PET/CT and 68 Ga-Pentixafor PET/CT Findings of Gastric Mucosa-associated Lymphoid Tissue Lymphoma Transformation to Diffuse Large B-cell Lymphoma.
- Minimally invasive treatment strategies for submucosal tumors of the upper gastrointestinal tract: Advances in innovative endoscopy-based therapies.
- XELOX combined with sintilimab and hyperbaric oxygen therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase Ib/II clinical trial.
- Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.
- Hyperbaric oxygen therapy as an immunosensitizing strategy in advanced gastric hepatoid adenocarcinoma: a case report.
- Integrated analysis of myeloperoxidase in gastric health and cancer: associations with pepsinogen levels, immune regulation, and prognosis in a large healthy population-based and TCGA cohorts.
- Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial.
- Identification of core immune-related genes CTSK, C3, and IFITM1 for diagnosing Helicobacter pylori infection-associated gastric cancer through transcriptomic analysis.
- Lidocaine Enhanced Antitumor Efficacy and Relieved Chemotherapy-Induced Hyperalgesia in Mice with Metastatic Gastric Cancer.
- Targeted inhibition of gastric adenocarcinoma by nano-curcumin liposomes: Insights from combined machine learning and experimental analyses into the mechanisms of cuproptosis and metabolic reprogramming.
- Impact of 68Ga-FAPI positron emission tomography/computed tomography on staging and tumor management in patients with gastric cancer.
- GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer.
- Effects of a Comprehensive Program on Reducing Cancer-Related Fatigue: A Randomized Controlled Trial.
- EZH2 loss promotes gastric squamous cell carcinoma.
- Alkannin triggered apoptosis and ferroptosis in gastric cancer by suppressing lipid metabolism mediated by the c-Fos/SREBF1 axis.
- miRNA-204-5p acts as a tumor suppressor in gastric cancer by inhibiting cell migration, invasion, and glycolysis via the RAB22A/PI3K/AKT axis.
- A novel prognostic model based on migrasome-related LncRNAs for gastric cancer.
- Disparities in overall survival of gastric cancer patients after radical gastrectomy: an age and rural-urban residence-based cohort study with propensity score matching analysis.
- Current status and influencing factors of cancer-related fatigue in gastric cancer patients undergoing chemotherapy: A cross-sectional study.
- The impact of Helicobacter pylori infection on prognosis in patients with postgastrectomy gastric cancer: A systematic review and meta-analysis.
- Correlation of preoperative CT features with intra- and postoperative parameters of endoscopic resection in patients with gastric submucosal tumor (1~3 cm).
- Intraperitoneal chemotherapy for gastric cancer.
- Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients.
- Efficacy and safety of S-1 plus oxaliplatin combined with apatinib and camrelizumab as neoadjuvant therapy for patients with locally advanced gastric or gastroesophageal junction adenocarcinoma: a protocol for a single-arm phase II trial.
- Comparison among Early-Onset, Late-Onset, and Conventional-Onset Adenocarcinoma of Stomach and Esophagogastric Junction: a Retrospective Study.
- A modified liver retraction method decreases liver dysfunction after laparoscopic gastrectomy.
- Enzyme-Responsive Branched Glycopolymer-Based Nanoassembly for Co-Delivery of Paclitaxel and Akt Inhibitor toward Synergistic Therapy of Gastric Cancer.
- Multicriteria optimization achieves superior normal tissue sparing in volumetric modulated arc therapy for gastric cancer.
- Endoscopic morphology of gastric MALT lymphoma correlate with API2/MALT1 fusion and predict treatment response after helicobacter pylori eradication.
- Chemotherapy combined with immunotherapy in patients with gastric cancer: protocol for a systematic review.
- Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial.
- Neoadjuvant and/or adjuvant chemotherapy for gastric cancer patients with microsatellite instability or deficient mismatch repair: a systematic review and meta-analysis study protocol.
- 68Ga-FAPI-04 positron emission tomography/CT and laparoscopy for the diagnosis of occult peritoneal metastasis in newly diagnosed locally advanced gastric cancer: study protocol of a single-centre prospective cohort study.
- Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
- Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer.
- Clinicopathological features of hepatoid adenocarcinoma and non-hepatoid adenocarcinoma of the stomach: A systematic review and meta-analysis.
- CAF-secreted LOX promotes PD-L1 expression via histone Lactylation and regulates tumor EMT through TGFβ/IGF1 signaling in gastric Cancer.
- Targeted plasma proteomic analysis uncovers a high-performance biomarker panel for early diagnosis of gastric cancer.
- Maintaining H. pylori Negativity After Eradication Can Consolidate Its Benefit in Gastric Cancer Prevention: A Meta-Analysis.
- Gastric Fundus Splenosis Mimicking Malignancy on FDG PET/CT.
- Malignant gastric outlet obstruction: direct biopsy in the submucosal tunnel to obtain the diagnosis.
- Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer.
- SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinica
- Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study.
- A novel suture technique for a large gastric defect after endoscopic full-thickness resection.
- Comment on "Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study".
- Combination of dexamethasone and dexmedetomidine as adjuvants of transversus abdominis plane block for postoperative analgesia in gastric cancer patients: A double-blinded randomized controlled trial.
- Gastrointestinal: Chronic anemia caused by diffuse lesions of the stomach.
- Development and Validation of a Computed Tomography-Based Model for Noninvasive Prediction of the T Stage in Gastric Cancer: Multicenter Retrospective Study.
- Structural Optimization and Structure-Activity Relationship of 1H-Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity.
- Involvement of CXC chemokines (CXCL1-CXCL17) in gastric cancer: Prognosis and therapeutic molecules.
- Symptom Cluster Assessment Tools for Gastric Cancer Care in China: A Comprehensive Review.
- The role of microRNAs in the gastric cancer tumor microenvironment.
- Gastric SMARCA4-deficient undifferentiated tumor (SMARCA4-UT): a clinicopathological analysis of four rare cases.
- Traditional Chinese medicine for gastric cancer: An evidence mapping.
- Optimal reconstruction methods after distal gastrectomy for gastric cancer: a protocol for a systematic review and network meta-analysis update.
- Gastric Cancer Signaling Pathways and Therapeutic Applications.
- Uncut Roux-en-Y reconstruction after distal gastrectomy for gastric cancer.
- Managing crawling-type gastric adenocarcinoma with endoscopic techniques and postoperative monitoring.
- Early gastric composite tumor comprising signet-ring cell carcinoma and mucosa-associated lymphoid tissue lymphoma: A case report.
- Exploring non-curative endoscopic submucosal dissection: Current treatment optimization and future indication expansion.
- Distinct oral-associated gastric microbiota and Helicobacter pylori communities for spatial microbial heterogeneity in gastric cancer.
- Effect of statin use on risk and mortality of gastric cancer: a meta-analysis.
- Trends in Incidence, Survival and Mortality of Gastric Cancer in the United States: A Population-Based Study, 2001-2015.
- Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
- CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia.
- Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.
- Comparison of long-term quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial.
- Hybrid Endoscopic Submucosal Dissection for Early Gastric Neoplasms: An Ideal Technique?
- Calcified fibrous tumor in the stomach: a rare case of gastric submucosal tumor treated with endoscopic submucosal excavation.
- Gastritis cystica profunda mimicking submucosal tumor.
- Successful resection of a cavernous hemangioma involving the rectal muscularis propria layer by endoscopic full-thickness resection.
- The impact of the Hedgehog signal pathway on the tumor immune microenvironment of gastric adenocarcinoma by integrated analysis of scRNA-seq and RNA-seq datasets.
- Active Eradication of Helicobacter pylori Within Organized Massive Screening Might Improve Survival of Gastric Cancer Patients.
- Krukenberg tumors metastasized from a T1a gastric carcinoma.
- The potential role of artificial intelligence besides predicting gastric cancer invasion depth.
- Discussion on the common controversies of Helicobacter pylori infection.
- Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.
- The investigation of volatile organic compounds in diagnosing (early) esophageal squamous cell carcinoma and gastric adenocarcinoma.
- Carrot and carotene and multiple health outcomes: an umbrella review of the evidence.
- Association between nut consumption and cancer risk: a meta-analysis.
- Prognostic role of pretreatment skeletal muscle index in gastric cancer patients: A meta-analysis.
- Whether preferences of gastric cancer patients after surgery for follow-up change over time? Analysis based on discrete choice experiment.
- A Gastrectomy for early-stage gastric cancer patients with or without preserving celiac branches of vagus nerves: A meta-analysis.
- Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.
- Clinical significance of tumor deposits in gastric cancer after radical gastrectomy: a propensity score matching study.
- Does endoscopic submucosal dissection have its place in the treatment of patients with gastric mucosa associated lymphoid tissue lymphoma localized disease after eradication?
- Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.
- Clinicopathological characteristics and survival outcomes of patients with gallbladder neuroendocrine tumor.
- Surgical replays-assisted diagnosis of duodenal stump fistula after laparoscopic radical distal gastrectomy (with video).
- Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
- Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.
- Dissecting the genetic and microenvironmental factors of gastric tumorigenesis in mice.
- Effects of EN combined with PN enriched with n-3 polyunsaturated fatty acids on immune related indicators and early rehabilitation of patients with gastric cancer: A randomized controlled trial.
- Feasibility of 3-dimensional-printed model assisting endoscopic resection of gastrointestinal submucosal tumors.
- Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery.
- Letter comments on: D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian gastric cancer study group D1 versus D2 randomised controlled trial.
- Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer:
- What is the clinical value of prediction models in the management of gastric cancer?
- Identifying Diagnostic and Prognostic Differentially Expressed Genes of Gastric Cancer Based on Bioinformatics Analyses of RNA-seq Data.
- Association of recurrent APOBEC3B alterations with the prognosis of gastric-type cervical adenocarcinoma.
- A commentary on "Safety and effectiveness of overlap esophagojejunostomy in totally laparoscopic total gastrectomy for gastric cancer: A systematic review and meta-analysis" (Int J Surg 2022; 102: 106684).
- A commentary on "Uncut Roux-en-Y might reduce the rate of reflux gastritis after radical distal gastrectomy: An evidence mapping from a systematic review" (Int J Surg 2022;97:106184).
- Application of artificial intelligence in the endoscopic diagnosis of early gastric cancer, atrophic gastritis, and Helicobacter pylori infection.
- Genetically predicted testosterone and cancers risk in men: a two-sample Mendelian randomization study.
- Clinical significance of lower perigastric lymph nodes dissection in Siewert type II/III adenocarcinoma of esophagogastric junction: a retrospective propensity score matched study.
- Immunological Perspective: Helicobacter pylori Infection and Gastritis.
- Multifactorial co-exposure within family of gastric cancer: increased risk of familial gastric cancer and tailored prevention.
- Deep learning-based AI model for signet-ring cell carcinoma diagnosis and chemotherapy response prediction in gastric cancer.
- Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
- Spicy Food and Chili Peppers and Multiple Health Outcomes: Umbrella Review.
- Effects of Preoperative Oral Nutritional Supplements on Improving Postoperative Early Enteral Feeding Intolerance and Short-Term Prognosis for Gastric Cancer: A Prospective, Single-Center, Single-Blind, Randomized Controlled Trial.
- Efficacy of early enteral nutrition versus total parenteral nutrition for patients with gastric cancer complicated with diabetes mellitus: A systematic review and meta-analysis.
- Helicobacter Pylori Related Gastric Cancer Screening and Cost-Effectiveness Analysis: A Hospital-Based Cross-Sectional Study (SIGES).
- The 'reversibility' of chronic atrophic gastritis after the eradication of Helicobacter pylori.
- Comparison of effectiveness and safety between endoscopic and surgical resection for 2-5 cm gastric stromal tumors.
- Artificial intelligence for diagnosing gastric lesions under white-light endoscopy.
- Assessment of indocyanine green fluorescence lymphography on lymphadenectomy during minimally invasive gastric cancer surgery: a systematic review and meta-analysis.
- Tibetan Ethnicity, Birthplace, Helicobacter pylori Infection, and Gastric Cancer Risk.
- Correlation of Autoimmune Pancreatitis and Risk of Gastric Cancer in East Asian Population.
- Comment on: Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
- Comment on: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma.
- Effectiveness and safety of robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a meta-analysis of 12,401 gastric cancer patients.
- Propensity score matching analysis for outcomes of laparoscopic versus open caudate lobectomy.
- Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study.
- Development and validation of RNA binding protein-applied prediction model for gastric cancer.
- Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
- The long-term survival outcomes of gastric cancer patients with total intravenous anesthesia or inhalation anesthesia: a single-center retrospective cohort study.
- Mixed adenoneuroendocrine carcinomas of stomach and ampulla of vater after curative-intent resection: a single center cases series.
- Long-term endoscopic submucosal dissection with postoperative lung injury: a case report.
- Laparoscopic infrapyloric lymph nodes dissection through the right bursa omentalis approach for gastric cancer.
- Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis.
- Impact of Surgical Margin Status on Survival in Gastric Cancer: A Systematic Review and Meta-Analysis.
- Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES).
- Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.
- The Impact of Nerve Involvement on the Prognosis of Gastric Cancer Patients with Curative Gastrectomy: An International Multicenter Analysis.
- Successful endoscopic submucosal dissection of a large juvenile polyp in the stomach of an infant.
- Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma.
- Tomato and lycopene and multiple health outcomes: Umbrella review.
- Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
- Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer.
- Taxifolin suppresses the malignant progression of gastric cancer by regulating the AhR/CYP1A1 signaling pathway.
- Gastrectomy with omentum preservation versus gastrectomy with omentectomy for locally advanced gastric cancer: A systematic review and meta-analysis.
- Monomorphic Epitheliotropic Intestinal T-cell Lymphoma of the Stomach: Two Case Reports and a Literature Review.
- Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
- The log odds of negative lymph nodes/T stage: a new prognostic and predictive tool for resected gastric cancer patients.
- Inflammatory bowel disease and risk of gastric, small bowel and colorectal cancer: a meta-analysis of 26 observational studies.
- Comparisons of perioperative and survival outcomes of laparoscopic versus open gastrectomy for serosa-positive (pT4a) gastric cancer patients: a propensity score matched analysis.
- Closure of Petersen's defect in gastrectomy for gastric cancer: an interrupted time series analysis from a high-volume institution in China.
- The value of spleen-preserving lymphadenectomy in total gastrectomy for gastric and esophagogastric junctional adenocarcinomas: A long-term retrospective propensity score match study from a high-volume institution in China.
- Application of clockwise modularized laparoscopic lymphadenectomy in the suprapancreatic area, a propensity score matching study and comparison with open gastrectomy.
- Incidence of adhesive small bowel obstruction after gastrectomy for gastric cancer and its risk factors: a long-term retrospective cohort study from a high-volume institution in China.
- Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.
- The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis.
Chinese-language papers (not in the count)18
- [Current status and trends of perioperative immunotherapy for gastric cancer].
- [Exploration of the lymph node dissection range and strategies for adenocarcinoma of esophagogastric junction from the perspective of membrane anatomy].
- [Application and clinical significance of the "Four-Step Procedure" of laparoscopic exploration in the diagnosis of gastric cancer with peritoneal metastasis].
- [Prudent promotion of new surgical techniques for functional preservation of gastric cancer].
- [Network Pharmacology Study of Compound Ligustrazine in Gastric Cancer Therapy].
- [Thinking about the extent and technique of lower mediastinal lymph nodes dissection for adenocarcinoma of esophagogastric junction].
- [Safety of patients undergoing radical resection combined with paclitaxel-based hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer].
- [Interpretation of Chinese expert consensus on the surgical treatment for adenocarcinoma of esophagogastric junction(2024 edition)].
- [Analysis and Treatment Experience of 25 Cases of Primary Gastric Lymphoma with Acute Upper Gastrointestinal Bleeding as the Primary Manifestation].
- [Clinical Value of White Light Image, Endoscopic Ultrasonography and Magnifying Endoscopy with Narrow Band Imaging in Evaluation of Indications for Endoscopic Treatment of Early Gastric Cancer].
- [Comparison of postoperative mid-term and long-term quality of life between Billroth-I gastroduodenostomy and Billroth-II gastrojejunostomy after radical distal gastrectomy in patients with gastric cancer: a cohort study based on a case reg
- [How to master the clinical study on digestive tract reconstruction in gastric cancer surgery].
- [Clinical significance of No.11p posterior lymph nodes dissection in gastric cancer surgery].
- [Treatment of Siewert type II adenocarcinoma of the esophagogastric junction: the perspectives from thoracic surgery].
- [MiR-4484 regulates the expression of integrin α 6 in gastric cancer tissues and its significance].
- [Utilizing Academic Clubs to Foster Practical Research Ability of Medical Students-Volunteer Team of Gastric Cancer Surgery of West China Hospital, Sichuan University].
- [Current status of diagnosis and treatment of gastric cancer peritoneal metastasis].
- [Risk factors of postoperative pulmonary infection of gastric cancer and perioperative intervention measures].
All its trials on ClinicalTrials.gov, any status51
- XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
- CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
- Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
- General Tissue Response Classification System After Chemotherapy
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Systematic Review and Meta-analysis of Cereal or Grain Consumption and Gastric Cancer
- Prospective Study on Double-Stapling End-to-End Gastroduodenostomy Billroth-I Anastomosis in Laparoscopy-Assisted Surgery for Locally Advanced Distal Gastric Cancers
- CT Radiomics and Deep Learning-Based Non-Invasive Model for Tracing Primary Sites of Adenocarcinoma Liver Metastases: Automatic Differentiation of Multiple Primary Digestive Tumors
- Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors
- Povidone-iodine and the Normal Saline Cleaning the Incision for the SSIs
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
- Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers
- Non-surgical Management After NIT for dMMR/MSI-H GC
- Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
- Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
- Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
- EpCAM CAR-T for Treatment of Advanced Solid Tumors
- Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer
- Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Metatinib Tromethamine Tablet
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
Cancer
Hepatoblastoma
肝母细胞瘤Led 4 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 2.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for hepatoblastoma88 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- β-Catenin regulates distinct pathways from YAP and suppresses ONECUT1 to drive hepatoblastoma development in mice and humans.
- Incidence and trends of hepatic cancer among children and adolescents in the United States from 2000 to 2017: Evidence from the Surveillance, Epidemiology, and End Results registry data.
- MRI-based deep learning model for differentiation of hepatic hemangioma and hepatoblastoma in early infancy.
- SOCS2 inhibits hepatoblastoma metastasis via downregulation of the JAK2/STAT5 signal pathway.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Chordoma
脊索瘤Led 3 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 2.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
Cancer
Osteosarcoma
骨肉瘤Led 36 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Chengdu for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led36
- KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.
- Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach.
- Sono-activable and biocatalytic 3D-printed scaffolds for intelligently sequential therapies in osteosarcoma eradication and defect regeneration.
- 3D-Printed Metacarpal Prosthesis in the Treatment of Primary Osteosarcoma of the First Metacarpal: A Novel Surgical Technique.
- 3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.
- Tetrahedral Framework Nucleic Acid-Loaded Retinoic Acid Promotes Osteosarcoma Stem Cell Clearance.
- Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis.
- Advancements in Photothermal Therapy Using Near-Infrared Light for Bone Tumors.
- Quality assessment of online osteosarcoma-related videos in Mainland China: A cross-sectional study.
- Surgical Treatment of Osteosarcoma Induced Distant Pre-Metastatic Niche in Lung to Facilitate the Colonization of Circulating Tumor Cells.
- Primary hepatic carcinosarcoma with osteosarcoma components: A case report and literature review.
- Bibliometric analysis of Ewing sarcoma from 1993 to 2022.
- Thiram, an inhibitor of 11ß-hydroxysteroid dehydrogenase type 2, enhances the inhibitory effects of hydrocortisone in the treatment of osteosarcoma through Wnt/β-catenin pathway.
- Advances of Osteosarcoma Models for Drug Discovery and Precision Medicine.
- The clinical characteristics, novel predictive tool, and risk classification system for primary Ewing sarcoma patients that underwent chemotherapy: A large population-based retrospective cohort study.
- Transformation of Cemento-Ossifying Fibroma into Osteosarcoma after Radiotherapy and Nine Endoscopic Surgeries.
- MiR-30 Family: A Novel Avenue for Treating Bone and Joint Diseases?
- Rare origin - Ewing's sarcoma of the pleura: a case report and literature review.
- Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.
- Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry.
- Synchronous lung and multiple soft tissue metastases developed from osteosarcoma of tibia: a rare case report and genetic profile analysis.
- Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?
- Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.
- Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma.
- Characteristics and prognosis of primary pulmonary osteosarcoma: a pooled analysis.
- Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.
- Use of Nomogram on Nutritional Assessment Indicators to Predict Clinical Outcomes in Patients Undergoing Surgical Resection for High-Grade Osteosarcoma.
- 3D Customized Biological Tibial Intramedullary Nail Fixation for the Treatment of Fracture after Massive Allograft Bone Transplantation of Tibial Osteosarcoma: A Case Report.
- The safety and efficiency of photodynamic therapy for the treatment of osteosarcoma: A systematic review of in vitro experiment and animal model reports.
- Primary Osteosarcoma of Left Atrial Appendage in a Patient with Rheumatic Heart Disease.
- A huge Ewing's sarcoma of the rib presenting with superior vena cava syndrome and dysphagia.
- 3D-Printed Multifunctional Polyetheretherketone Bone Scaffold for Multimodal Treatment of Osteosarcoma and Osteomyelitis.
- 3D Printed Multifunctional Ti6Al4V-Based Hybrid Scaffold for the Management of Osteosarcoma.
- Progress of Phototherapy Applications in the Treatment of Bone Cancer.
- Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma.
- Askin tumor in the chest wall.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)22
- PTEN in osteosarcoma: Recent advances and the therapeutic potential.
- Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
- Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway.
- A nomogram for predicting cancer-specific survival in patients with osteosarcoma as secondary malignancy.
- RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.
- Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.
- Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma.
- Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
- SP1-induced upregulation of long non-coding RNA HCP5 promotes the development of osteosarcoma.
- Total ulna replacement with a 3D-printed custom-made prosthesis after en bloc tumor resection: A case report.
- Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.
- [Therapeutic Effect of Uncemented Allograft-prosthetic Composite for the Reconstruction of Tumorous Bone Defect].
- Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis.
- Uncemented three-dimensional-printed prosthetic reconstruction for massive bone defects of the proximal tibia.
- Integrated bioinformatics analysis of miRNA expression in osteosarcoma.
- Successful removal of giant primary osteosarcoma in the anterior mediastinum invading the superior vena cava and right lung with artificial blood vessel reconstruction.
- Primary Left Atrial Osteosarcoma.
- A multi-level comparative analysis of human femoral cortical bone quality in healthy cadavers and surgical safe margin of osteosarcoma patients.
- A case report of apatinib in treating osteosarcoma with pulmonary metastases.
- Antidifferentiation Noncoding RNA Regulates the Proliferation of Osteosarcoma Cells.
- A rare case of extensive primary meningeal osteosarcoma in childhood.
- Congenital Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature.
All its trials on ClinicalTrials.gov, any status1
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 33 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 6.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
6 hospitals in Chengdu for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07379047
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led33
- Development and validation of CT-based nomograms for predicting recurrence and prognosis in gastrointestinal stromal tumor.
- NF1 Mutated Gastrointestinal Stromal Tumors With Coamplification of MDM2 and MYC.
- Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature.
- Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study.
- The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: a propensity score-matched analysis.
- FDG PET/CT Image of Extragastrointestinal Stromal Tumor in the Posterior Mediastinum.
- Gastrointestinal stromal tumors regulate macrophage M2 polarization through the MIF/CXCR4 axis to immune escape.
- Analysis of the diagnostic value of CT radiomics models in differentiating GIST and other mesenchymal tumors.
- Wild-type gastrointestinal stromal tumors with NTRK gene fusions: A clinicopathological study.
- Surgical treatment of the metastatic gastrointestinal stromal tumor after resistance to available tyrosine kinase inhibitors: A case report.
- Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature.
- Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
- Impact of surgical resection for gastrointestinal stromal tumor (GIST) patients with initially diagnosed synchronous hepatic metastases on long-term survival outcomes.
- DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis.
- Two-staged hepatectomy for bilobar metastases of the gastrointestinal stromal tumor (GIST).
- Primary hepatic gastrointestinal stromal tumor: A case series.
- Open and minimally invasive surgery for gastrointestinal stromal tumours: a systematic review and network meta-analysis protocol.
- The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65.
- Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
- Feasibility of 3-dimensional-printed model assisting endoscopic resection of gastrointestinal submucosal tumors.
- Cap-assisted endoscopic full-thickness resection for small gastrointestinal stromal tumors.
- Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
- Surgical strategies for duodenal gastrointestinal stromal tumors.
- Comparison of effectiveness and safety between endoscopic and surgical resection for 2-5 cm gastric stromal tumors.
- Prognostic significance of hemoglobin, albumin, lymphocyte, platelet in gastrointestinal stromal tumors: A propensity matched retrospective cohort study.
- Use of computed tomography for distinguishing heterotopic pancreas from gastrointestinal stromal tumor and leiomyoma.
- Primary retroperitoneal gastrointestinal stromal tumor mimicking adrenal mass: A case report.
- Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal stromal tumors, and the significance of neoadjuvant therapy.
- Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors.
- Gastric neoplasm: Gastrointestinal stromal tumor mimicking gastric carcinoma.
- Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review.
- Surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a protocol for a systematic review and meta-analysis update.
- Transperineal core-needle biopsy of a rectal subepithelial lesion guided by endorectal ultrasound after contrast-enhanced ultrasound: A case report.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)28
- Current and Potential Applications of Artificial Intelligence in Gastrointestinal Stromal Tumor Imaging.
- Identification of gastrointestinal stromal tumors from leiomyomas in the esophagogastric junction: A single-center review of 136 cases.
- Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
- [Efficacy of Transcatheter Embolization for Gastrointestinal Stromal Tumor with Gastrointestinal Hemorrhage in 17 Cases].
- Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study.
- [Clinical diagnosis and treatment of gastrointestinal stromal tumor: matching technological breakthrough with patient care].
- Endoscopic full-thickness resection for a duodenal gastrointestinal stromal tumour.
- PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
- Primary Gastrointestinal Stromal Tumor of the Liver.
- Diffuse ileal ganglioneuromatosis mimicking a gastrointestinal stromal tumor: A case report.
- Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion: A case report and systematic literature review.
- Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs.
- Proteomic Maps of Human Gastrointestinal Stromal Tumor Subgroups.
- Association between CT imaging features and KIT mutations in small intestinal gastrointestinal stromal tumors.
- [Real world study and its application in gastrointestinal stromal tumor].
- Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.
- Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: A systematic review and meta-analysis.
- Comparison Analysis of Three Different Types of Minimally Invasive Procedures for Gastrointestinal Stromal Tumors ≤5 cm.
- Effect of Gastrointestinal Bleeding on Gastrointestinal Stromal Tumor Patients: A Retrospective Cohort Study.
- Giant gastric stromal tumor mimicking as a posterior mediastinal mass: A case report and literature review.
- Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
- Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study.
- [Associations of Preoperative Platelet-to-lymphocyte Ratio and Derived Neutrophil-to-lymphocyte Ratio with thePrognosis of Gastrointestinal Stromal Tumor].
- [FAP Expression and Its Association with the Prognosis of Gastric Stromal Tumors].
- Laparoscopic Versus Open Resection for Gastric Gastrointestinal Stromal Tumors (GISTs): A Size-Location-Matched Case-Control Study.
- Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
- A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment.
- [Preliminary understanding of gastrointestinal stromal tumor with the highest risk].
All its trials on ClinicalTrials.gov, any status6
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
Cancer
Neuroblastoma
神经母细胞瘤Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials as a site
- 0
- led by another institution
8 hospitals in Chengdu for neuroblastoma352 hospitals in China for neuroblastoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
- Phase
- Early phase 1
- Started
- 2026-07
- Registry
- NCT07767630
Age 1 year to 100 years (registered criteria)
Led by West China HospitalChengdu
- RecruitingSafety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma
- Phase
- Early phase 1
- Started
- 2025-07
- Registry
- NCT07067346
Age 12 months to Not stated (registered criteria)
Led by West China HospitalChengdu
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- TSPYL5-driven G3BP1 nuclear membrane translocation facilitates p53 cytoplasm sequestration via accelerating RanBP2-mediated p53 sumoylation and nuclear export in neuroblastoma.
- The Complementary Role of 68 Ga-FAPI-04 PET/CT in a Case of Neuroblastoma.
- Contrast computed tomography-based radiomics is correlation with COG risk stratification of neuroblastoma.
- Extracellular matrix stiffness controls VEGF165 secretion and neuroblastoma angiogenesis via the YAP/RUNX2/SRSF1 axis.
- Hyperthermia in a pediatric patient with neuroblastoma during anesthesia: a case report.
Earlier papers (2016–2020)5
- The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH.
- Primary orbital ganglioneuroblastoma in a child: A case report.
- The effect of age distribution on the prognosis of retroperitoneal neuroblastoma.
- Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis.
- Primary cervical ganglioneuroblastoma: A case report.
All its trials on ClinicalTrials.gov, any status3
Cancer
Ewing sarcoma
尤文肉瘤Led 9 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 5.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led9
- KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma.
- 3D-Printed Talus-Calcaneus Prosthesis in Treating Ewing's Sarcoma: A Case Report.
- Bibliometric analysis of Ewing sarcoma from 1993 to 2022.
- The clinical characteristics, novel predictive tool, and risk classification system for primary Ewing sarcoma patients that underwent chemotherapy: A large population-based retrospective cohort study.
- Rare origin - Ewing's sarcoma of the pleura: a case report and literature review.
- Comment on: Membrane-type 1 matrix metalloproteinase as predictor of survival and candidate therapeutic target in Ewing sarcoma.
- Primary Ewing sarcoma/peripheral primitive neuroectodermal tumors in the cranial bone and mobile spine: what is the difference?
- A huge Ewing's sarcoma of the rib presenting with superior vena cava syndrome and dysphagia.
- Askin tumor in the chest wall.
Chinese-language papers (not in the count)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 59 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 3.5%.
- Open trials led
- 0
- recruiting or about to
2 hospitals in Chengdu for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07255898
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingA Clinical Study of SHR-9539 in Patients With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-08
- Registry
- NCT06484777
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingPurinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Registry
- NCT06484829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu
- RecruitingA Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06700395
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai
- RecruitingA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Phase
- Phase 4
- Started
- 2022-03
- Registry
- NCT05201781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led59
- Single-cell RNA sequencing reveals immune regulatory mechanisms and molecular therapeutic strategies in the microenvironment of multiple myeloma.
- Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation.
- LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma.
- The mitochondrial protease ClpP is a promising target for multiple myeloma treatment.
- A disulfidptosis-related gene signature predicts prognosis and immune-metabolic landscape in multiple myeloma.
- Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma.
- Navigating the Prognostic Complexity of IgH Cytogenetic Abnormalities in Multiple Myeloma Among Diverse IgH Cytogenetic Abnormalities-Involved High-Risk Stratifications.
- Bortezomib enhances the efficacy of BCMA CAR-T therapy through up-regulating BCMA expression in myeloma cells.
- Beneficial effects of aerobic exercises on multiple myeloma: Mechanisms and clinical observations.
- A comprehensive analysis of bone marrow-derived cytogenetic abnormalities in multiple myeloma patients with extramedullary disease.
- Impact of integrated nursing care on rehabilitation process of inpatients with multiple myeloma in an academic hematology department.
- Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.
- Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
- Delivery of CD47-SIRPα checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma.
- RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
- A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China.
- Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.
- Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib.
- Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.
- Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.
- CAR-T Therapy in Relapsed Refractory Multiple Myeloma.
- Clinical significance of T helper cell subsets in the peripheral blood and bone marrow of patients with multiple myeloma.
- Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
- BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
- Multiple myeloma: signaling pathways and targeted therapy.
- Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
- Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.
- Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.
- Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
- Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
- BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
- Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: A UK biobank cohort study.
- Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma.
- A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma.
- Hypermetabolic Subserosal Uterine Leiomyoma With Synchronous Atypical Multiple Myeloma Mimicking Ovarian Malignancy With Multiple Bone Metastases on 18F-FDG PET/CT.
- Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
- Case report: Vesiculobullous eruption with an atypical IgA deposition pattern in a patient with multiple myeloma-A case report and literature review.
- Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
- A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy.
- Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.
- Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey.
- Body Mass Index and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies.
- Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing.
- ALCAM regulates multiple myeloma chemoresistant side population.
- Site-specific N-glycosylation characterization of micro monoclonal immunoglobulins based on EThcD-sceHCD-MS/MS.
- False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
- ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
- Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease.
- FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma.
- Symptom clusters and quality of life in ambulatory patients with multiple myeloma.
- Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.
- Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomise
- Extramedullary intracardiac multiple myeloma misdiagnosed as a thrombus: a case report.
- BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.
- Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.
- Multiple Myeloma Presenting as Disseminated Osteoblastic Lesions With Intense 18F-FDG Uptake on PET/CT.
- Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma.
- Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
- Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
Chinese-language papers (not in the count)5
- [Advances in Modeling of Multiple Myeloma in Mice].
- [Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].
- [Receptor Activator of Nuclear Factor κB Ligand-Receptor Activator of Nuclear Factor κB Signaling Pathway in Myeloma Bone Disease].
- [Full-cycle Health Management of Multiple Myeloma].
- [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
All its trials on ClinicalTrials.gov, any status21
- CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma
- Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
- A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of Daratumumab
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
2 hospitals in Chengdu for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
- Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase Ib Clinical Study of Keynatinib
- Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 4 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for aplastic anaemia63 hospitals in China for aplastic anaemia
No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- The diagnostic value and clinical correlations of bone marrow supernatant S100A8 and S100A9 in myelodysplastic neoplasms.
- Diagnosis and Management of Fanconi Anemia.
- Efficacy and safety of eltrombopag in Chinese patients with refractory or relapsed severe aplastic anemia.
- Umbilical cord-derived mesenchymal stem cells cultured in the MCL medium for aplastic anemia therapy.
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 12 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 3.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led12
- Flow cytometric analysis of the immune cell subsets in adult hemophagocytic lymphohistiocytosis.
- Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.
- Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review.
- Sulfasalazine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) coinfected with COVID-19 complicated by hemophagocytic lymphohistiocytosis: a case report.
- Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.
- Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis.
- The predictive value of hematological inflammatory markers for acute kidney injury and mortality in adults with hemophagocytic Lymphohistiocytosis: A retrospective analysis of 585 patients.
- A prediction model for acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.
- Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients.
- Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center.
- Clinical features and prognostic factors of acute kidney injury caused by adult secondary hemophagocytic lymphohistiocytosis.
- Case Report: Visceral Leishmaniasis-associated Hemophagocytic Lymphohistiocytosis in Adults: A Case Series and Literature Review.
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)18
- Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis
- Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis
- Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis
- Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital
- Chronic active EBV infection with hemophagocytic lymphohistiocytosis and progression to aggressive NK cell leukemia
- Clinical Characteristics and Prognosis of Subcutaneous Panniculitis-like T-Cell Lymphoma Based on the SEER Database
- Pharmacological and Mechanism Study of a New RIPK1 Inhibitor Via Necroptosis to Treat Hemophagocytic Lymphohistiocytosis
- Herombopag, a Second Generation Thrombopoietin-Receptor Agonist, Stimulates Platelet Engraftment after Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
- Additional file 2 of NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
- Clinical Characteristics of Hemophagocytic Lymphohistiocytosis in Adults with Central Nervous System Involvement
- Familial hemophagocytic lymphohistiocytosis with Epstein–Barr virus infection and progression to aggressive NK-cell leukemia: a case report and review of the literature
- Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone
- Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
- Risk factors of in-hospital death in pediatric patients with hemophagocytic lymphohistiocytosis: A case-control study
- Risk factors of in-hospital death in pediatric patients with hemophagocytic lymphohistiocytosis: A case-control study
- Chronic active EB virus infection with hemophagocytic lymphohistiocytosis and progression to aggressive NK cell leukemia: a case report and review of the literature
- Development and Initial Validation of a Novel Prognostic Model in Adult Secondary Hemophagocytic Lymphohistiocytosis Patients: Experience From a Single-center Retrospective Study
- MO412THE RISK FACTORS OF ACUTE KIDNEY INJURY CAUSED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Blood disorders
Beta thalassaemia
β 地中海贫血Led 2 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
6 hospitals in Chengdu for beta thalassaemia157 hospitals in China for beta thalassaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Phase
- Phase 2
- Started
- 2019-11
- Registry
- NCT04143724
Age 6 years to 17 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
- Case Report: Abnormally Low Glycosylated Hemoglobin A1c Caused by Clinically Silent Rare β-Thalassemia in a Tujia Chinese Woman.
- A Triple-Heterozygous β-Thalassemia Patient Demonstrated an Unusual Electrophoresis Pattern Due to a Novel β0 Mutation [an IVS-II-654 (C>T) mutation with a Hb Zürich-Langstrasse (HBB: c.151A>T) mutation in cis].
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Haemophilia A
血友病 ALed 4 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Chengdu for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Clinical outcomes of total hip and knee arthroplasty for end-stage hemophilic arthropathy in patients with hemophilia: a retrospective study.
- Perioperative Hematological Outcomes of Simultaneous Double Total Joint Arthroplasty for Hemophilic Arthritis of the Hip and Knee: A Retrospective Study.
- Efficacy and Safety of Adeno-Associated Virus-Based Clinical Gene Therapy for Hemophilia: A Systematic Review and Meta-Analysis.
- Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 2 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chengdu for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Fanconi anaemia
范可尼贫血Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 36 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 7.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led36
- Glymphatic dysfunction in neuromyelitis optica spectrum disorder.
- Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.
- Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.
- Progressive retinal and microvascular neurodegeneration in neuromyelitis optica spectrum disorders: a longitudinal SS-OCT/OCTA study.
- Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.
- A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.
- Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.
- Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab.
- Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection.
- Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
- Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.
- Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
- Initial BMI effects on clinical presentation and prognosis in neuromyelitis optica spectrum disorder.
- COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study.
- Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models.
- Retinal structural and microvascular changes in myelin oligodendrocyte glycoprotein antibody disease and neuromyelitis optica spectrum disorder: An OCT/OCTA study.
- Non-immune system comorbidity in neuromyelitis optica spectrum disorders.
- Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder.
- Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
- Investigation on marital status of patients with neuromyelitis optica spectrum disorders in China.
- Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders.
- Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks.
- Brain structural and functional connectivity alterations are associated with fatigue in neuromyelitis optica spectrum disorder.
- Granzyme B in circulating CD8+ T cells as a biomarker of immunotherapy effectiveness and disability in neuromyelitis optica spectrum disorders.
- The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases.
- Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.
- Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
- Sparser macula microvasculature in neuromyelitis optica spectrum disorder occurs independently of optic neuritis.
- Mortality of neuromyelitis optica spectrum disorders in a Chinese population.
- CD8+ T cell subpopulations and pro-inflammatory cytokines in neuromyelitis optica spectrum disorder.
- The immune regulatory effects of tetrahedral framework nucleic acid on human T cells via the mitogen-activated protein kinase pathway.
- Neuromyelitis Optica Spectrum Disorder With Hyponatremia as an Initial Presentation: A Case Report.
- Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases.
- Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
- Brain changes correlate with neuropathic pain in patients with neuromyelitis optica spectrum disorders.
- Hemorrhagic encephalitis in a patient with neuromyelitis optica: A case report.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Other diseases
IgG4-related disease
IgG4相关性疾病Led 11 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 4.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Chengdu for IgG4-related disease46 hospitals in China for IgG4-related disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07061938
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Immunoglobulin G4-related disease with pleural involvement in an 80-year-old female patient: A case report and literature review.
- IgG4-related disease presenting with hypercalcemia: case report and mechanistic insights.
- Case Report: IgG4-RD-related ophthalmopathy combined with monoclonal gammopathy of undetermined significance.
- Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease.
- Similarities and differences of a proliferation-inducing ligand expression in lacrimal gland lesions of patients with IgG4-associated ophthalmic diseases and mucosa-associated lymphoid tissue lymphoma.
- Immunoglobulin G4-related ophthalmic disease with orbital deep hemangioma: A case report.
- Clinicopathologic features and outcomes of bilateral lacrimal gland lesions.
- Clinical Significance of Serum IgG4 in the Diagnosis and Treatment Response of IgG4-Related Disease in Adults of Southwest China: A Retrospective Study.
- Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease.
- Malignancies in Chinese patients with immunoglobulin G4-related disease.
- IgG4-Related Disease With Tuberculosis: A Case Report and Retrospective Review of Patients in a Single Center.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)1
Other diseases
Myasthenia gravis
重症肌无力Led 16 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 3.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Chengdu for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06463587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi
- RecruitingEfficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05067348
Age 18 years to 80 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an
- RecruitingA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04951622
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led16
- The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.
- The Role of Exosomes in Central Immune Tolerance and Myasthenia Gravis.
- Clinical study of thyroid eye disease combined with myasthenia gravis.
- Identification of Novel Protein Biomarkers for Myasthenia Gravis by Integrating Human Proteomics with Genetic Instruments.
- The mortality of myasthenia gravis with myocarditis: A single-center retrospective study.
- The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.
- Impact of body mass index on clinical presentation and prognosis in myasthenia gravis.
- Efficacy and Safety of Tacrolimus Therapy in Patients With Juvenile Myasthenia Gravis: A Single-Arm Meta-Analysis.
- The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection.
- Mendelian randomization study revealed a gut microbiota-neuromuscular junction axis in myasthenia gravis.
- Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?
- Association between COVID-19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study.
- Unexpected fibrous mediastinitis in a patient with myasthenia gravis - a case report.
- Safety and feasibility of a modularized procedure for trans-subxiphoid robotic extended thymectomy.
- More ectopic thymic tissues resection results in a better outcome for patients with myasthenia gravis†.
- Sexual dysfunction in patients with myasthenia gravis.
All its trials on ClinicalTrials.gov, any status8
- Myasthenia Gravis Registry in China
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 11 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Chengdu for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Drug-Coated Balloon Treatment for LAD CTO in a Young Woman With Moyamoya Disease Guided by Intravascular Imaging.
- Association between angiographic and clinical outcomes after STA-MCA bypass in adult moyamoya disease.
- Long-term outcomes after revascularization surgery for adult moyamoya disease: Protocol for systematic review and meta-analysis.
- Successful perioperative management of a patient undergoing laparoscopic colon surgery with high-risk of cerebral ischemia due to moyamoya disease.
- Ivy Sign: Usefulness in Diagnosis and Prognosis Prediction of Moyamoya Disease.
- Nomogram to Predict Good Collateral Formation After the STA-MCA Bypass Surgery in Adult Patients With Moyamoya Disease.
- Imaging methods for surgical revascularization in patients with moyamoya disease: an updated review.
- Angiographic and Hemodynamic Features in Asymptomatic Hemispheres of Patients With Moyamoya Disease.
- Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease in Adults with Moyamoya Disease.
- Hemorrhagic stroke caused by moyamoya disease in a patient with obstructive hypertrophic cardiomyopathy.
- Clinical and Hemodynamic Features in Moyamoya Disease with Intracranial Aneurysms.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Biliary atresia
胆道闭锁Led 7 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 3.3%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for biliary atresia28 hospitals in China for biliary atresia
No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led7
- Sequential treatment strategy for biliary atresia: Kasai hepatoportoenterostomy-liver transplantation: a single-center retrospective comparative cohort study.
- Diagnostic performance and prognostic value of elastography in patients with biliary atresia and after hepatic portoenterostomy: protocol for a systematic review and meta-analysis.
- ANKRD1 and SPP1 as diagnostic markers and correlated with immune infiltration in biliary atresia.
- Medium-term outcomes after laparoscopic revision of laparoscopic Kasai portoenterostomy in patients with biliary atresia.
- Laparoscopic Kasai portoenterostomy for cystic biliary atresia: midterm follow-up results of 35 patients.
- The short-term outcome of modified laparoscopic Kasai portoenterostomy for biliary atresia.
- Congenital biliary atresia is correlated with disrupted cell junctions and polarity caused by Cdc42 insufficiency in the liver.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 22 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 8.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led22
- Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
- Peripheral T-cell subset activation in NMDAR encephalitis: Insights into pathogenesis and biomarker potential for disease monitoring.
- Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
- The potential role of tACS in improving cognitive dysfunction associated with anti-NMDAR encephalitis.
- Antibody-secreting cells as a source of NR1-IgGs in N-methyl-D-aspartate receptor-antibody encephalitis.
- Intestinal dysbiosis exacerbates susceptibility to the anti-NMDA receptor encephalitis-like phenotype by changing blood brain barrier permeability and immune homeostasis.
- Cortical atrophy in early-stage patients with anti-NMDA receptor encephalitis: a machine-learning MRI study with various feature extraction.
- Efficacy and safety of different oral prednisone tapering courses in adult anti-NMDAR encephalitis: A multicenter prospective cohort study.
- Blood and CSF findings of cellular immunity in anti-NMDAR encephalitis.
- Genome-Wide Association Study Identifies IFIH1 and HLA-DQB1*05:02 Loci Associated With Anti-NMDAR Encephalitis.
- Single-cell RNA sequencing reveals diverse B cell phenotypes in patients with anti-NMDAR encephalitis.
- Patient characteristics and outcome in patients with anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis.
- Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update.
- Efficacy and tolerability of intravenous immunoglobulin versus intravenous methylprednisolone treatment in anti-N-methyl-d-aspartate receptor encephalitis.
- Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis.
- Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.
- Case Report: Overlapping Syndrome of Anti-NMDAR Encephalitis and MOG Inflammatory Demyelinating Disease in a Patient With Human Herpesviruses 7 Infection.
- Electroconvulsive therapy in a patient with positive anti-NMDA receptor antibodies presenting with isolated psychiatric symptoms: A case report.
- Temporal rank of clinical characteristics and prognosis of anti-N-methyl-d-aspartate receptor encephalitis.
- Disturbance of Gut Bacteria and Metabolites Are Associated with Disease Severity and Predict Outcome of NMDAR Encephalitis: A Prospective Case-Control Study.
- High Dose Steroids as First-Line Treatment Increased the Risk of In-Hospital Infections in Patients With Anti-NMDAR Encephalitis.
- Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)18
- Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients.
- Reply: Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation.
- Risk factors for pneumonia in patients with anti-NMDA receptor encephalitis: A single-center retrospective study.
- Long-term cognitive and neuropsychiatric outcomes in patients with anti-NMDAR encephalitis.
- Alterations in the human gut microbiome in anti-N-methyl-D-aspartate receptor encephalitis.
- Late-onset anti-N-methyl-d-aspartate receptor encephalitis in China.
- Allergy in patients with anti-N-methyl-d-aspartate receptor encephalitis.
- Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.
- Massive idiopathic spontaneous hemothorax complicating anti-N-methyl-d-aspartate receptor encephalitis: A case report.
- Risk factors for mortality in patients with anti-NMDA receptor encephalitis: Reply to comment on data sparsity.
- Risk factors for mortality in patients with anti-NMDA receptor encephalitis.
- Case report of anti-N-methyl-D-aspartate receptor encephalitis in a middle-aged woman with a long history of major depressive disorder.
- Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study.
- Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases.
- Suicidality is a common and serious feature of anti-N-methyl-D-aspartate receptor encephalitis.
- Comparisons between Psychiatric Symptoms of Patients with Anti-NMDAR Encephalitis and New-Onset Psychiatric Patients.
- Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China.
- Anti-N-methyl-D-aspartate receptor encephalitis: a common cause of encephalitis in the intensive care unit.
Other diseases
Takayasu arteritis
大动脉炎Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
Earlier papers (2016–2020)6
- Restenosis of Bilateral Aorta-Renal Saphenous Vein Grafts after the Surgical Repair of Takayasu Arteritis-induced Bilateral Renal Arteries Stenosis: Case Report.
- Interventional therapy for Takayasu arteritis with pulmonary artery and pulmonary vein stenosis.
- Risk of rupture of an aortorenal vein graft aneurysm after the surgical repair of Takayasu arteritis-induced right renal artery stenosis: A case report and a literature review.
- Aneurysmal Degeneration of an Aortorenal Bypass for Takayasu Renal Artery Stenosis: A Novel Endovascular Intervention.
- A Case of Takayasu Arteritis With the Ostium of Left Main Coronary Artery Obstructed by Prolapsed Thickened Ascending Aortic Intima.
- Treatment of severe hypertension in a 14-year-old child: Successful blood pressure control with additive administration of captopril, an angiotensin-converting enzyme inhibitor, in a patient with bilateral renovascular hypertension.
Other diseases
Hepatic echinococcosis
肝包虫病Led 14 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 9.2%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led14
- High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.
- Epidemiology and Clinical Characteristics of Cerebral Alveolar Echinococcosis in the Tibetan Region of Sichuan, China.
- Pictorial review of hepatic echinococcosis: Ultrasound imaging and differential diagnosis.
- Two-step resection procedure for advanced hepatic alveolar echinococcosis: First case-series report.
- Lung and brain recurrence after liver transplantation for advanced alveolar echinococcosis: A case report.
- Successful laparoscopic anatomical resection of segments V and VIII for hepatic alveolar echinococcosis with diaphragmatic involvement: A case report.
- Can contrast-enhanced ultrasound differentiate the type of hepatic echinococcosis: cystic echinococcosis or alveolar echinococcosis?
- Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis.
- Two-stage hepatectomy combined with middle hepatic vein reconstruction in a patient with complicated hepatic alveolar echinococcosis.
- Severe hypernatremia in children after surgical resection of hepatic echinococcosis: a rare and potentially fatal complication.
- Application of ex vivo liver resection and autotransplantation in treating Budd-Chiari syndrome secondary to end-stage hepatic alveolar echinococcosis: A case series.
- Treatment of retroperitoneal echinococcosis: the experience of a single center.
- Triphase contrast-enhanced CT to evaluate indications for autologous liver transplantation in patients with end-stage hepatic alveolar echinococcosis.
- Hydatid Pulmonary Embolism: A Case Report and Literature Review.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)22
- Another case of hepatic alveolar echinococcosis?
- Individualized biliary reconstruction techniques in autotransplantation for end-stage hepatic alveolar echinococcosis.
- Epidemiological characteristics of hepatic echinococcosis, concurrent cerebral echinococcosis, and pulmonary echinococcosis in Ganzi County, Sichuan Province, China.
- Preoperative nutritional evaluation of patients with hepatic alveolar echinococcosis.
- Outcomes of different surgical resection techniques for end-stage hepatic alveolar echinococcosis with inferior vena cava invasion.
- Ex vivo liver resection and autotransplantation versus allotransplantation for end-stage hepatic alveolar echinococcosis.
- Remnant Liver-to-Standard Liver Volume Ratio Below 40% is Safe in Ex Vivo Liver Resection and Autotransplantation.
- Transhepatic-intrahepatic branches of the portal vein catheterization for ex vivo liver resection and autotransplantation: Two case reports of novel approach to perfuse the liver.
- Doughnut sign of hepatic alveolar echinococcosis on FDG PET/CT: Clinical case report.
- The role of contrast-enhanced ultrasound in the diagnosis of hepatic alveolar echinococcosis.
- Surgical approaches for definitive treatment of hepatic alveolar echinococcosis: results of a survey in 178 patients.
- Vascular infiltration-based surgical planning in treating end-stage hepatic alveolar echinococcosis with ex vivo liver resection and autotransplantation.
- Residual cavity hydrops initially misdiagnosed as recurrent hepatic echinococcosis.
- Novel techniques and preliminary results of ex vivo liver resection and autotransplantation for end-stage hepatic alveolar echinococcosis: A study of 31 cases.
- The choose of different surgical therapies of hepatic alveolar echinococcosis: A single-center retrospective case-control study.
- Ultrasonographic findings of small lesion of hepatic alveolar echinococcosis.
- Risk factors and a simple model for predicting bile leakage after radical hepatectomy in patients with hepatic alveolar echinococcosis.
- The association of hypernatremia and hypertonic saline irrigation in hepatic hydatid cysts: A case report and retrospective study.
- Two-stage hepatectomy for multiple giant alveolar echinococcosis.
- Hepatectomy for patients with alveolar echinococcosis: Long-term follow-up observations of 144 cases.
- Multiorgan resection with inferior vena cava reconstruction for hepatic alveolar echinococcosis: A case report and literature review.
- Hepatic Vein Injuries During Laparoscopic Hepatectomy.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 31 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
16 hospitals in Chengdu for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led31
- Biomimetic Topological Micropattern Arrays Regulate the Heterogeneity of Cellular Fates in Lung Fibroblasts between Fibrosis and Invasion.
- Discovery of novel capsaicin analogs as TRPV1 inhibitors for the treatment of idiopathic pulmonary fibrosis.
- The Ketone Body β-Hydroxybutyrate Mitigates the Ferroptosis of Alveolar Epithelial Cells Type II in Bleomycin-Induced Pulmonary Fibrosis.
- CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS.
- Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.
- Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis.
- The value of macrolides in the adjuvant treatment of pulmonary fibrosis: maybe a panacea.
- Tetrahedral Framework Nucleic Acids Delivery of Pirfenidone for Anti-Inflammatory and Antioxidative Effects to Treat Idiopathic Pulmonary Fibrosis.
- INTEGRIS-IPF: A New Hope for Tomorrow.
- Acute exacerbation of idiopathic pulmonary fibrosis disease: a diagnosis model in China.
- Buyang Huanwu decoction ameliorates bleomycin-induced pulmonary fibrosis in rats by attenuating the apoptosis of alveolar type II epithelial cells mediated by endoplasmic reticulum stress.
- Authors' Reply to Letter to the Editor Regarding the Article "Genetic Association of Circulating Adipokines with Risk of Idiopathic Pulmonary Fibrosis: a Two-Sample Mendelian Randomization Study".
- Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes.
- Diagnostic and prognostic value of secreted phosphoprotein 1 for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
- Discovery of indoline-based derivatives as effective ROCK2 inhibitors for the potential new treatment of idiopathic pulmonary fibrosis.
- AAV9-Tspyl2 gene therapy retards bleomycin-induced pulmonary fibrosis by modulating downstream TGF-β signaling in mice.
- Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.
- Discovery of the novel Benzo[b]thiophene 1,1-dioxide derivatives as a potent STAT3 inhibitor against idiopathic pulmonary fibrosis.
- Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis.
- Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
- Diabetic endothelial microangiopathy and pulmonary dysfunction.
- Decreased Th1 Cells and Increased Th2 Cells in Peripheral Blood Are Associated with Idiopathic Inflammatory Myopathies Patients with Interstitial Lung Disease.
- Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.
- Genetic Association of Circulating Adipokines with Risk of Idiopathic Pulmonary Fibrosis: A Two-Sample Mendelian Randomization Study.
- Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
- Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis.
- Role of Circular RNAs in Pulmonary Fibrosis.
- Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study.
- Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.
- Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.
- Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
- Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis.
- Mitochondrial dysfunction and chronic lung disease.
- In Silico Detection and Characterization of microRNAs and Their Target Genes in microRNA Microarray Datasets from Patients with Systemic Sclerosis-Interstitial Lung Disease.
- Identification of novel inhibitors of DDR1 against idiopathic pulmonary fibrosis by integrative transcriptome meta-analysis, computational and experimental screening.
All its trials on ClinicalTrials.gov, any status12
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 2 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 4.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 60 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 7.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
8 hospitals in Chengdu for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06556394
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led60
- Untargeted metabolomics based on LC-MS and GC-MS reveal metabolic reprogramming and putative biomarkers in amyotrophic lateral sclerosis.
- Loss of Y chromosome and its implications in male amyotrophic lateral sclerosis: insights from the UK Biobank.
- Genetically Predict Diet-derived Antioxidants and Risk of Neurodegenerative Diseases Among Individuals of European Descent: A Mendelian Randomization Study.
- Mutation Screening of ATXN1, ATXN2, and ATXN3 in Amyotrophic Lateral Sclerosis.
- Association between Psychiatric Disorders and Amyotrophic Lateral Sclerosis: A Prospective Cohort Study from the UK Biobank.
- Association between metabolic syndrome, its individual components and progression of amyotrophic lateral sclerosis.
- Association of creatinine level with neurodegenerative disorders: a prospective cohort study and Mendelian randomization analysis.
- Viral infections and the risk of neurodegenerative diseases: a comprehensive meta-analysis and systematic review.
- Association between sleep and ALS-FTSD: A Prospective Cohort Study based on 396,918 UK biobank participants.
- Peripheral immunity relate to disease progression and prognosis in amyotrophic lateral sclerosis.
- The C9orf72-SMCR8 complex suppresses primary ciliogenesis as a RAB8A GAP.
- TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.
- Causal relationship between PCSK9 inhibitor and common neurodegenerative diseases: A drug target Mendelian randomization study.
- Differential cortical gray matter changes in early- and late-onset patients with amyotrophic lateral sclerosis.
- Genotype-phenotype correlation of SQSTM1 variants in patients with amyotrophic lateral sclerosis.
- Amyotrophic lateral sclerosis patients with various gene mutations show diverse motor phenotypes and survival in China.
- Clinical and genetic characteristics of ALS patients with variants in genes regulating DNA methylation.
- Genome-wide DNA methylation analysis related to ALS patient progression and survival.
- The Long Non-Coding RNA NR3C2-8:1 Promotes p53-Mediated Apoptosis through the miR-129-5p/USP10 Axis in Amyotrophic Lateral Sclerosis.
- Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.
- Lnc-HIBADH-4 Regulates Autophagy-Lysosome Pathway in Amyotrophic Lateral Sclerosis by Targeting Cathepsin D.
- Rare DNAJC7 Variants May Play a Minor Role in Chinese Patients with ALS.
- Abnormal Brain Protein Abundance and Cross-tissue mRNA Expression in Amyotrophic Lateral Sclerosis.
- Total physical activity, plant-based diet and neurodegenerative diseases: A prospective cohort study of the UK biobank.
- Downregulation of Lnc-ABCA12-3 modulates UBQLN1 expression and protein homeostasis pathways in amyotrophic lateral sclerosis.
- BL-918, a small-molecule activator of ULK1, induces cytoprotective autophagy for amyotrophic lateral sclerosis therapy.
- Association between vascular risk factors and cognitive impairment in amyotrophic lateral sclerosis: a case-control study.
- Genetic Modifiers of Age at Onset for Amyotrophic Lateral Sclerosis: A Genome-Wide Association Study.
- TBK1 variants in Chinese patients with amyotrophic lateral sclerosis: Genetic analysis and clinical features.
- Multisite chronic pain and the risk of autoimmune diseases: A Mendelian randomization study.
- Mutation screening of SPTLC1 and SPTLC2 in amyotrophic lateral sclerosis.
- Identifying novel genes for amyotrophic lateral sclerosis by integrating human brain proteomes with genome-wide association data.
- Physical activity as risk factor in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- Genetic and Phenotypic Spectrum of Amyotrophic Lateral Sclerosis Patients with CCNF Variants from a Large Chinese Cohort.
- Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis.
- Genetic and clinical characteristics of ALS patients with NEK1 gene variants.
- ALS-linked C9orf72-SMCR8 complex is a negative regulator of primary ciliogenesis.
- Venous blood parameters in determination of respiratory impairment in amyotrophic lateral sclerosis.
- Sleep in amyotrophic lateral sclerosis: A systematic review and meta-analysis of polysomnographic findings.
- A case of juvenile-onset amyotrophic lateral sclerosis with a de novo frameshift FUS gene mutation presenting with bilateral abducens palsy.
- Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.
- Spatial-temporal pattern of propagation in amyotrophic lateral sclerosis and effect on survival: A cohort study.
- A Prediction Model for Peak Expiratory Flow Derived From Venous Blood Biomarkers and Clinical Factors in Amyotrophic Lateral Sclerosis.
- Lack of association of TP73 rare variants with amyotrophic lateral sclerosis in a Chinese cohort.
- Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population.
- The role of Th17 cells/IL-17A in AD, PD, ALS and the strategic therapy targeting on IL-17A.
- The expression discrepancy and characteristics of long non-coding RNAs in peripheral blood leukocytes from amyotrophic lateral sclerosis patients.
- Mutation Screening of TFG in α-Synucleinopathy and Amyotrophic Lateral Sclerosis.
- Genetic analysis of and clinical characteristics associated with ANXA11 variants in a Chinese cohort with amyotrophic lateral sclerosis.
- The progress in C9orf72 research: ALS/FTD pathogenesis, functions and structure.
- Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases.
- Early weight instability is associated with cognitive decline and poor survival in amyotrophic lateral sclerosis.
- Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis.
- Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.
- Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- The Evaluation of Pain with Nociceptive and Neuropathic Characteristics from Three Different Perspectives in Amyotrophic Lateral Sclerosis Patients: A Case Controlled Observational Study in Southwestern China.
- Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study.
- Mutation screening and burden analysis of GLT8D1 in Chinese patients with amyotrophic lateral sclerosis.
- Disruption of the white matter structural network and its correlation with baseline progression rate in patients with sporadic amyotrophic lateral sclerosis.
- Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)38
- Effects of Exercise in Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis.
- Serum creatinine levels in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- The C9orf72-SMCR8-WDR41 complex is a GAP for small GTPases.
- LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice.
- MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis.
- Causal Association of Leukocytes Count and Amyotrophic Lateral Sclerosis: a Mendelian Randomization Study.
- Cryo-EM structure of C9ORF72-SMCR8-WDR41 reveals the role as a GAP for Rab8a and Rab11a.
- Patterns of brain regional functional coherence in cognitive impaired ALS.
- Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis.
- Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis.
- Neurophysiological index is associated with the survival of patients with amyotrophic lateral sclerosis.
- Mutation screening of the KIF5A gene in Chinese patients with amyotrophic lateral sclerosis.
- Unique characteristics of the genetics epidemiology of amyotrophic lateral sclerosis in China.
- An association study between SCFD1 rs10139154 variant and amyotrophic lateral sclerosis in a Chinese cohort.
- Clinical and prognostic features of ALS/MND in different phenotypes-data from a hospital-based registry.
- Determining the Effect of the HNMT, STK39, and NMD3 Polymorphisms on the Incidence of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy in Chinese Populations.
- Altered white matter microarchitecture in amyotrophic lateral sclerosis: A voxel-based meta-analysis of diffusion tensor imaging.
- Mutation screening of the TIA1 gene in Chinese patients with amyotrophic lateral sclerosis/frontotemporal dementia.
- Meta-analysis of the association between ZNF512B polymorphism rs2275294 and risk of amyotrophic lateral sclerosis.
- The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.
- Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population.
- Absence of association of the Ala58Val (rs17571) CTSD gene variant with Parkinson's disease or amyotrophic lateral sclerosis in a Han Chinese population.
- White matter volume loss in amyotrophic lateral sclerosis: A meta-analysis of voxel-based morphometry studies.
- Why might ALS have negative effects on patients with out-of-hospital cardiac arrest?
- [Roles of exosomes in Parkinson's disease and amyotrophic lateral sclerosis].
- Patients' self-perceived burden, caregivers' burden and quality of life for amyotrophic lateral sclerosis patients: a cross-sectional study.
- Association analysis of polymorphisms in VMAT2 and TMEM106B genes for Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy.
- HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort.
- Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis.
- Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival.
- Analysis of SOD1 mutations in a Chinese population with amyotrophic lateral sclerosis: a case-control study and literature review.
- Associations between neuropsychiatric symptoms and cognition in Chinese patients with amyotrophic lateral sclerosis.
- Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.
- Mutational analysis of CHCHD2 in Chinese patients with multiple system atrophy and amyotrophic lateral sclerosis.
- SLC1A2 rs3794087 are associated with susceptibility to Parkinson's disease, but not essential tremor, amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population.
- Large C9orf72 repeat expansions are seen in Chinese patients with sporadic amyotrophic lateral sclerosis.
- Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.
- No association of GPNMB rs156429 polymorphism with Parkinson's disease, amyotrophic lateral sclerosis and multiple system atrophy in Chinese population.
All its trials on ClinicalTrials.gov, any status2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Chengdu for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy
No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Fabry disease
法布雷病Led 5 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 6.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Chengdu for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Screening for Fabry disease in patients with hypertrophic cardiomyopathy using cardiac magnetic resonance imaging.
- Left Ventricular Hemodynamic Forces Changes in Fabry Disease: A Cardiac Magnetic Resonance Study.
- GLA deficiency causes cardiac hypertrophy via enhanced autophagy.
- Identification of c.146G > A mutation in a Fabry patient and its correction by customized Cas9 base editors in vitro.
- Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status3
Other diseases
Pompe disease
庞贝病Led 2 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 6.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Behçet disease
白塞病Led 6 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 2.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chengdu for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Surgery for pseudoaneurysm following the Bentall procedure in a patient with Behçet's disease: A case report.
- Life-Threatening Involvement of Bilateral Pulmonary Arteries in Behçet Disease on FDG PET.
- 'Caterpillar-like' pseudoaneurysms in Behçet's disease.
- Gastrointestinal Behçet Disease Secondary to Myelodysplastic Syndrome.
- Chronic active Epstein-Barr virus infection manifest as extensive mucocutaneous ulceration mimicking Behçet's disease.
- Prosthetic valve detachment complicated with intervalvular fibrous body destruction in Behcet's disease: a case report.
Earlier papers (2016–2020)5
- A right ventricular mass in a young man with Behçet's disease: A case report.
- Behcet's disease involved the root of aorta in the treatment with modified Bentall procedure: a case report.
- Vocal cord involvement and hoarseness in a patient with Behcets disease: A rare case report.
- Sudden unilateral vision loss in an adult with Behcet disease: A case report.
- Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review.
Other diseases
Alport syndrome
Alport 综合征Led 2 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 3.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
IgA nephropathy
IgA 肾病Led 34 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 4.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
9 hospitals in Chengdu for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led34
- 2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation.
- Particulate matter exposure and end-stage renal disease risk in IgA nephropathy.
- High systemic inflammatory response index (SIRI) is an independent risk factor for poor outcome in IgA nephropathy patients.
- Risk Stratification in Immunoglobulin A Nephropathy Using Network Biomarkers: Development and Validation Study.
- Association between different proportions of crescents and adverse renal outcomes in immunoglobulin a nephropathy: a systematic review and meta-analysis.
- Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.
- Personalized decision support system for tailoring IgA nephropathy treatment strategies.
- Demographic distribution analysis of different glomerular diseases in Southwest China from 2008 to 2022.
- Fabry Disease with Genetic Variants of Unknown Significance and Concomitant Immunoglobulin A Nephropathy.
- Combined Effects of the Serum IgA/C3 Ratio and Glomerular C3 Staining on the Renal Outcome in Adult Immunoglobulin A Nephropathy.
- The clinical and pathological evaluation of patients with immunoglobulin A nephropathy by diffusion tensor imaging and intravoxel incoherent motion diffusion-weighted imaging.
- Nephrotic proteinuria and hematuria with newly diagnosed IgA nephropathy after liver transplant: A case report.
- Altered serum metabolic profile in patients with IgA nephropathy.
- Association of obesity with the development of end stage renal disease in IgA nephropathy patients.
- Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis.
- Roles of mesangial C3 and C1q deposition in the clinical manifestations and prognosis of IgAN.
- Uric acid-based ratios for predicting renal failure in Chinese IgA nephropathy patients.
- Characterization of site-specific N-glycosylation signatures of isolated uromodulin from human urine.
- IgA Nephropathy in a Patient With Metastatic Carcinoma of Unknown Primary: Findings on 18F-FDG PET/MRI.
- Prognostic Value of Triglyceride to High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in IgA Nephropathy Patients.
- Platelet-to-Albumin Ratio: A Novel IgA Nephropathy Prognosis Predictor.
- Association of genetic polymorphisms in IL-23R and IL-17A with the susceptibility to IgA nephropathy in a Chinese Han population.
- Prognostic value of the albumin-to-fibrinogen ratio (AFR) in IgA nephropathy patients.
- The Ratio of CD226 and TIGIT Expression in Tfh and PD-1+ICOS+Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
- Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling.
- Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy.
- Cigarette smoking may accelerate the progression of IgA nephropathy.
- Mesangial IgM deposition predicts renal outcome in patients with IgA nephropathy: a multicenter, observational study.
- Epigenome-wide association study and network analysis for IgA Nephropathy from CD19+ B-cell in Chinese Population.
- High Neutrophil-To-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy.
- Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients.
- Sex disparities in IgA nephropathy: a retrospective study in Chinese patients.
- Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
- A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy.
Earlier papers (2016–2020)13
- Modifications of gut microbiota are associated with the severity of IgA nephropathy in the Chinese population.
- Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
- Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy.
- The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis.
- [Effect of serum IgA/C3 and glomerular C3 staining on clinical prognosis in patients with IgA nephropathy].
- Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.
- IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy.
- Crescents and Global Glomerulosclerosis in Chinese IgA Nephropathy Patients: A Five-Year Follow-Up.
- Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
- Interleukin 18 -607 A/C Gene Polymorphism is Associated With Susceptibility to IgA Nephropathy in a Chinese Han Population.
- MicroRNA-155-induced T lymphocyte subgroup drifting in IgA nephropathy.
- The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA).
- Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy.
All its trials on ClinicalTrials.gov, any status6
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
Other diseases
Gaucher disease
戈谢病Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chengdu for Gaucher disease41 hospitals in China for Gaucher disease
No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 11 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 3.7%.
- Open trials led
- 0
- recruiting or about to
4 hospitals in Chengdu for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led11
- Association of sarcopenia assessed by CT/MRI with treatment response and clinical outcomes in noncirrhotic primary biliary cholangitis patients.
- Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.
- Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.
- Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
- Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome.
- Factors and cytokine signatures associated with the response to therapy in patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome: a real-world study.
- Hematologic traits and primary biliary cholangitis: a Mendelian randomization study.
- Causal associations between inflammatory bowel disease and primary biliary cholangitis: a two-sample bidirectional Mendelian randomization study.
- Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome.
- Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis.
- Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)9
- Primary biliary cholangitis with autoimmune hepatitis features: What's the appropriate criteria to evaluate the treatment-response?
- Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis.
- Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography in patients with primary biliary cholangitis.
- Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis.
- Severe anemia caused by hereditary hemorrhagic telangiectasia in a patient with Sjögren's syndrome and primary biliary cirrhosis.
- Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
- Genetic association of E26 transformation specific sequence 1 polymorphisms with the susceptibility of primary biliary cholangitis in China.
- Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.
- Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-yr cohort study involving 769 patients.
All its trials on ClinicalTrials.gov, any status12
- Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1
- Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy
- Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II
- A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis
- The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital
- A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome
- Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
- Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 3 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 3.0%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Apremilast as a novel therapeutic option for psoriasis coexisting primary sclerosing cholangitis and ulcerative colitis: A case report.
- Causality of immune cells on primary sclerosing cholangitis: a bidirectional two-sample Mendelian randomization study.
- Liver transplantation in a child with liver cirrhosis caused by langerhans cell histiocytosis: a case report.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status1
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led 5 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 8.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chengdu for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led5
- Global birth prevalence of major congenital anomalies: a systematic review and meta-analysis.
- Fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia: systematic review and meta-analysis.
- A rare Bochdalek hernia in an adult: a case report.
- Emergency Management of Acute Late-Presenting Congenital Diaphragmatic Hernia in Infants and Children.
- Do B-type natriuretic peptide levels accurately predict outcome in infants with congenital diaphragmatic hernia?
Earlier papers (2016–2020)4
- Another type of diaphragmatic hernia to remember: parahiatal hernia.
- Thoracoscopic Treatment of Late-Presenting Congenital Diaphragmatic Hernia in Infants and Children.
- Minimally invasive surgery for congenital diaphragmatic hernia: a meta-analysis.
- [OBSERVATION OF EFFECTIVENESS OF THORACOSCOPIC SURGERY FOR LATEPRESENTING CONGENITAL DIAPHRAGMATIC HERNIA].
Other diseases
Hirschsprung disease
先天性巨结肠Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led 4 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 7.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chengdu for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Novel compound heterozygous mutations of the COL7A1 gene in a Chinese patient with recessive dystrophic epidermolysis bullosa pruriginosa and digestive symptoms successfully treated with tofacitinib.
- A heterozygous mutation in ITGB4 causing a mild phenotype of junctional epidermolysis bullosa.
- Exon 8 deletion of KRT5 in epidermolysis bullosa simplex with mottled pigmentation: A case report.
- Identification of novel compound heterozygous ITGB4 mutations in a Chinese woman with junctional epidermolysis bullosa without pylori atresia but profound urinary symptoms: A case report and review of the literature.
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 2 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 6.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chengdu for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
四川大学华西医院
West China Hospital
成都
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
West China Hospital of Sichuan University; Sichuan University West China Hospital; West China Hospital Sichuan University; West China Hospital Sichuan University Chengdu Sichuan China; Digestive Endoscopic Center of West China Hospital; Biomedical Big Data Center of West China Hospital; Operation Room of West China Hospital; Chengdu Shang Jin Nan Fu Hospital West China Hospital